



Systematic Review Association between Serum Lactate and Morbidity and Mortality in Neonates: A Systematic Review and Meta-Analysis

Felipe Yu Matsushita ^{1,2,*}, Vera Lucia Jornada Krebs ^{1,2}, and Werther Brunow De Carvalho ^{1,2}

- ¹ Department of Pediatrics, Neonatology Division, Faculty of Medicine, University of São Paulo, São Paulo 01246-903, Brazil; vera.krebs@hc.fm.usp.br (V.L.J.K.); werther.brunow@hc.fm.usp.br (W.B.D.C.)
- ² Instituto da Criança, Av. Dr. Enéas de Carvalho Aguiar, 647, São Paulo 05403-000, Brazil
 - * Correspondence: felipe.matsushita@hc.fm.usp.br; Tel.: +55-(11)-981800848

Abstract: Objective: Lactate is a marker of hypoperfusion in critically ill patients. Whether lactate is useful for identifying and stratifying neonates with a higher risk of adverse outcomes remains unknown. This study aimed to investigate the association between lactate and morbidity and mortality in neonates. Methods: A meta-analysis was performed to determine the association between blood lactate levels and outcomes in neonates. Ovid MEDLINE, EMBASE, Cochrane Library, and ClinicalTrials.gov were searched from inception to 1 May 2021. A total of 49 observational studies and 14 data accuracy test studies were included. The risk of bias was assessed using the Newcastle-Ottawa Scale for observational studies and the QUADAS-2 tool for data accuracy test studies. The primary outcome was mortality, while the secondary outcomes included acute kidney injury, necessity for renal replacement therapy, neurological outcomes, respiratory morbidities, hemodynamic instability, and retinopathy of prematurity. Results: Of the 3184 articles screened, 63 studies fulfilled all eligibility criteria, comprising 46,069 neonates. Higher lactate levels are associated with mortality (standard mean difference, -1.09 [95% CI, -1.46 to -0.73]). Using the estimated sensitivity (0.769) and specificity (0.791) and assuming a prevalence of 15% for adverse outcomes (median of prevalence among studies) in a hypothetical cohort of 10,000 neonates, assessing the lactate level alone would miss 346 (3.46%) cases (false negative) and wrongly diagnose 1776 (17.76%) cases (false positive). Conclusions: Higher lactate levels are associated with a greater risk of mortality and morbidities in neonates. However, our results do not support the use of lactate as a screening test to identify adverse outcomes in newborns. Research efforts should focus on analyzing serial lactate measurements, rather than a single measurement.

Keywords: lactate; newborn; mortality; critical illness; preterm; neonates

1. Introduction

Lactate is a powerful parameter that can be used to indirectly assess the hemodynamic system, but only when used correctly [1]. In critically ill patients, lactate is a classical marker, where its elevation is associated with greater morbidity and mortality [1]. Hyperlactatemia is a hallmark parameter in shock states because of lactate production in anaerobic metabolism, representing a state where there is an inadequate oxygen supply [2]. In adult and pediatric literature, there is strong evidence that lactate is a predictor of mortality [3,4]. Unfortunately, evidence about the utility of lactate measurement in neonates is limited.

There is no consensus regarding the treatment of hemodynamic instability in neonates, especially in preterm infants [5]. Moreover, classical parameters that are used to evaluate the cardiovascular system such as blood pressure alone are still not reliable in the neonatal period. Currently, there still is no definition for hypotension in neonates, nor a consensus of whether its correction is beneficial [6].

In this context, being able to use a parameter that aids in the diagnosis and treatment of hemodynamic instability in newborns would be valuable. The aim of this systematic review



Citation: Matsushita, F.Y.; Krebs, V.L.J.; De Carvalho, W.B. Association between Serum Lactate and Morbidity and Mortality in Neonates: A Systematic Review and Meta-Analysis. *Children* **2023**, *10*, 1796. https://doi.org/10.3390/ children10111796

Academic Editor: Joaquim M. B. Pinheiro

Received: 14 September 2023 Revised: 4 November 2023 Accepted: 6 November 2023 Published: 8 November 2023



Copyright: © 2023 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https:// creativecommons.org/licenses/by/ 4.0/).

2 of 21

and meta-analysis was to determine the association between blood lactate concentration and morbidity and mortality in neonates.

2. Material and Methods

This systematic review and meta-analysis followed the recommendations based on the PRISMA (Preferred Reporting Items for Systematic Reviews and Meta-analysis) [7] and the Cochrane Centre for Reviews and Dissemination [8]. The search strategy was developed according to recommendations of PRESS [9] (Peer Review of Electronic Search Strategies) and was executed in May 2021. Ovid MEDLINE, EMBASE, Cochrane Library, and trial registries were searched without publication or language restrictions (see the Search Strategy in Figure S1). All references from retrieved citations were searched for additional relevant studies. The Rayyan web app [10] was used for study selection and initial abstract and title screening. The PRISMA flowchart is presented in Figure 1. We did not find any randomized controlled trials. Data extraction was performed by two authors (FYM and VLJK) and plotted in a previously built structured data extraction form. Any unresolved discrepancies of extracted data were resolved by a third author (WBC).




Figure 1. Flowchart—Preferred Reporting Items for Systematic Reviews and Meta-Analysis (PRISMA).

Two authors (FYM and VLJK) independently screened titles and abstracts and reviewed them. When the title and abstract were insufficient to decide on eligibility criteria, the full text was retrieved. If there was an unresolved disagreement, a third author (WBC) was consulted. All selected studies were retrieved and applied to a predefined inclusion criterion. The eligibility criteria included: (1) the study covered a neonatal population or a specific neonatal subgroup analyzed separately (<6 weeks postnatal age or < corrected gestational age of 40 weeks); (2) the study had at least one lactate measurement with a defined time assessment point; and (3) the study reported at least one outcome of interest. Studies

that included pediatric patients were only eligible if data for neonates could be extracted separately. Studies reported only as abstracts were eligible only if sufficient information was available. If multiple articles analyzed the same set of patients, we included only the article with the largest number of neonates. This systematic review and meta-analysis followed the previously published protocol registered with the PROSPERO International Prospective Register of Systematic Reviews (CRD42021253329). Protocol changes are given in the Supplementary Material.

The primary objective was to evaluate the impact of hyperlactatemia on mortality in neonates during hospital stay. Composite outcomes with survival data were analyzed as mortality. Secondary outcomes included acute kidney injury, renal replacement therapy necessity, neurological outcomes, respiratory morbidities, hemodynamic instability, and retinopathy of prematurity.

We grouped the timing of lactate assessment into two different groups: early (lactate measured within 3 days of life or less) and late (lactate measured after more than 3 days of life). Lactate collected from the umbilical cord was analyzed separately. Initially, we planned to divide the lactate collected from venous and arterial sources, but due to insufficient data from the studies, this division was not possible. If studies assessed lactate at multiple time points, the earliest post-condition/intervention point or the highest value was selected. Hyperlactatemia was defined according to each study definition.

We assessed the risk of bias of included studies using the Newcastle-Ottawa Scale [11] for nonrandomized studies. A study with a total score of 7 or higher was considered of good quality, a study with a score of 4 to 6 was considered of fair quality, and a study with a score of lower than 4 was considered of poor quality. To assess the risk of bias of diagnostic accuracy studies, we used the QUADAS-2 tool [12].

For dichotomous variables, we used the odds ratio (OR) as the common measure of association with its respective 95% confidence interval. Lactate as a continuous variable was reported as standard mean differences (SMDs) with their respective 95% confidence interval. When studies reported medians and interquartile intervals, we used Wan et al.'s formula to infer the mean value and standard deviation [13]. To meta-analyze, we used random-effects models as proposed by Der Simonian and Laird because of the anticipated heterogeneity between studies. Statistical analysis was performed using RevMan 5 (Review Manager 5) software, v5.4, The Cochrane Collaboration. Heterogeneity was analyzed by performing subgroup analysis based on subgroup population and was measured using I^2 statistics where estimates higher than 50% were considered as indicating significant heterogeneity. A *p*-value lower than 0.05 was considered statistically significant.

Following the recommendations from the Cochrane Screening and Diagnostic Test Methods Group, one author (FYM) extracted diagnostic data and derived the number of true-positive, false-positive, true-negative, and false-negative cases. A second author (VLJK) checked the extracted data, and if a consensus was not reached, a third author (WBC) was consulted. We then created forest plots with 95% confidence intervals (Cis) for sensitivity and specificity using RevMan 5 (Review Manager 5) software, v5.4, The Cochrane Collaboration. A hierarchical summary ROC model was used because the reported cutoff levels for lactate differed among included studies. A meta-analysis of diagnostic test accuracy studies was performed using MetaDTA (web-based tool v2.0) [14], and estimates of sensitivity and specificity were calculated. Heterogeneity was assessed by analyzing the forest plots of sensitivity and specificity across studies.

3. Results

Among 3184 records, a total of 185 potentially relevant articles were screened and fully retrieved (Figure 1). Of those, 63 studies, including 46,069 newborns (sample sizes ranged from 16 to 21,182 neonates), met the full inclusion criteria (Tables 1 and S1). No randomized controlled trials were found. Studies excluded from the systematic review and the justification for their exclusion are presented in Table S2. The majority of studies (57%) were conducted in North America and Europe, 20 were conducted in Asia-Oceania, 6 were

conducted in Latin America, and 1 was conducted in Africa. All studies were published between 1994 and 2021, with most studies (46 of 63) published after 2010. Among the studies, 14 evaluated lactates in preterm infants, 13 evaluated lactates in neonates with infants with congenital heart disease (CHD), and 12 evaluated lactates in neonates with birth asphyxia. The mean lactate levels in the nonsurvivor group varied between 2.2 and 23.42 mmoL/L. After applying the Newcastle-Ottawa Scale, 36 studies were labeled as being of good quality and 13 as fair quality (Table S3). The main potential sources of bias were "Representativeness of cohort" and "Comparability".

We identified 14 studies analyzing lactate in data accuracy tests, comprising 39,540 patients. The characteristics of the included studies are summarized in Table S1. The cut-off levels for lactate ranged from 2.5 to 9.95 mmoL/L. The main potential source of bias was "Patient Selection".

3.1. Mortality

We found 32 studies analyzing hyperlactatemia as a continuous variable and mortality, comprising 2562 patients. Those who survived had lower lactate levels compared to nonsurvivors (SMD, -1.09 [95% CI, -1.46 to -0.73]; I² = 92%; p < 0.00001). Eight studies evaluated mortality as part of the composite outcome. We grouped studies with similar neonatal populations, resulting in five subgroups: (1) congenital heart disease (SMD, -0.72 [95% CI, -1.38 to -0.06]; I² = 92%; n = 826; p = 0.03); (2) birth asphyxia (SMD, -1.01 [95% CI, -1.71 to -0.32]; I² 82%; n = 402; p = 0.004); (3) ECMO (SMD, -1.87 [95% CI, -3.47 to -0.27]; I² = 96%; n = 287; p < 0.02); (4) preterm (SMD, -1.52 [95% CI, -2.67 to -0.73]; I² 96%; n = 706; p = 0.009); and (5) term (SMD, -1.09 [95% CI, -1.11 to -0.32]; I² = 51%; n = 341; p = 0.0004) (Figure 2). When dividing studies according to the time of lactate assessment, we categorized them into two different groups: (1) early (<3 days of life) (SMD, -0.92 [95% CI, -1.31 to -0.53], I² = 79%; n = 1009; p < 0.00001) and (2) late (>3 days of life) (SMD, -1.2 [95% CI, -1.74 to -0.67], I² = 94%; n = 1553; p < 0.0001) (Figure 3). The heterogeneity among studies was considerable (I² = 92% for an overall impact of hyperlactatemia).

Author	Year	Country	Study Type	Subgroup Population	No. Patients	Gestational Age	Birth Weight (kg)	Outcomes
Charpie JR [15]	2000	USA	РС	CHD	46	-	3.2 (0.5)	Death or ECMO
Polackova R [16]	2017	Czech republic	PC	Birth Asphyxia	51	38.8 (1.8)—adverse outcome group	3.2 (0.6)—adverse outcome group	Death or severe disability
Lekhwani S [17]	2010	India	RC	All	50	-	-	Death
Tokuhisa T [18]	2014	Japan	CC	Birth Asphyxia	23	38.5 (1.3)—adverse outcome group	2.9 (0.7)—adverse outcome group	Death or cerebral palsy
Matsushita FY [19]	2019	Brazil	RC	Preterm	80	26.1 (2.1)	0.66 (0.14)	Death
Buijs EAB [20]	2014	Netherlands	PC	ECMO	56	-	3 (2.2–3.3)	Death
Photiadis J [21]	2006	Germany	PC	CHD	26	-	3.3 (0.1)—nonsurvivor group	Death
Amirnovin R [22]	2013	USA	PC	CHD	24	-	3.3 (0.4)	Death OR surgical intervention OR ECMO OR transplant
Li J [23]	2012	Japan	RC	Birth Asphyxia	21	39.2 (1.9)—poor outcome group	2.8 (0.4)—poor outcome group	Death or neurological deficit
Shuhaiber J [24]	2012	USA	CC	CHD	112		25% with birth weight < 2.5 kg—nonsurvivor group	Death
Hayakawa M [25]	2014	Japan	RC	Birth Asphyxia	227	36.6 (38.4–40.6)	2.9 (2.6–3.2)	Death or neurological deficit
Joffe AR [26]	2007	Canada	РС	CHD	70	39 (2)	3.3 (0.6)	Death
Manotas H [27]	2017	Colombia	RC	Birth Asphyxia	64	-	-	Death
Liu X [28]	2020	China	RC	CHD	207	-	3 (0.5)—nonsurvivor group	Death
Ouellete C [29]	2019	USA	RC	Sepsis	12	-	-	Death
Miyamoto T [30]	2008	Germany	RC	CHD	34	35.5 (2.3)	2.1 (0.2)	Death
Rocha TS [31]	2010	Brazil	RC	CHD	76	-	3.1 (0.4)—nonsurvivor group	Death
Howard TS [32]	2016	USA	RC	CHD	84	-	2.9 (2.3–3.1)—nonsurvivor group	Death
Groenendaal F [33]	2003	Netherlands	RC	Preterm	79	28.5 (2.3)—poor outcome group	1.1 (0.5)—poor outcome group	Death or cerebral palsy
Christmann M [34]	2018	Switzerland	RC	CHD	57	-	2.9 (0.5)—nonsurvivor group	Death
Cheung PY [35]	1994	Canada	RC	ECMO	28	38.3 (2.1)—nonsurvivors	3 (0.4)—nonsurvivors	Death
Phillips LA [36]	2011	UK	PC	Preterm	381	28 (23–37)	1 (0.37–1.5)	Death

Table 1. Characteristics of the included studies in the systematic review.

Table 1. Cont.

Author	Year	Country	Study Type	Subgroup Population	No. Patients	Gestational Age	Birth Weight (kg)	Outcomes
Kessler U [37]	2006	Switzerland	RC	Preterm/NEC	128	28.7 (0.8)—nonsurvivors	1.2 (0.12)—nonsurvivors	Death
Abubacker M [38]	2002	UK	RC	Preterm/NEC	24	27 (24–36)— nonsurvivors	0.7 (0.5–1.8)—nonsurvivors	Death
Verheijen PM [39]	2010	Netherlands	RC	CHD	105	-	-	Death
Araki S [40]	2010	Japan	RC	Birth Asphyxia	16	35.6 (4.5)—nonsurvivors	2.3 (0.7)—nonsurvivors	Death
Erdeve O [41]	2019	Turkey	РС	All	372	31.1 (5.4)—nonsurvivors	1.65 (1.09)—nonsurvivors	Death or ECMO
Chen D [42]	2020	China	РС	All	161	31.9 (3.5)—nonsurvivors	1.95 (0.53)—nonsurvivors	Death
Cheung PY [43]	2002	Canada	PC	ECMO	74	39 (2)	3.2 (0.7)	Death
Cheung PY [44]	2005	Canada	PC	CHD	85	38 (1)—nonsurvivors	3.1 (0.55)—nonsurvivors	Death
Reppucci ML [45]	2020	USA	RC	Preterm/GI perforation	42	-	BW < 1500 g	Death
Grayck EN [46]	1995	USA	RC	ECMO	82	-	-	Death/intracranial hemorrhage
Fernandez HGC [47]	2012	Brazil	RC	All	156	33.1 (4)— hyperlactatemia	1.83 (0.88)—hyperlactatemia	Death/seizure/pulmonary hypertension/intracerebral hemorrhage
Márquez-González H [48]	2015	Mexico	РС	All	154	18% > 37 weeks— nonsurvivors	22% > 2500 g—nonsurvivors	Death
Márquez-González- H [48]	2015	Mexico	РС	All	227	-	-	Death
Murtuza B [49]	2011	Switzerland	RC	CHD	221	-	3.1 (0.6)	Death
Okur N [50]	2018	Turkey	РС	Preterm	119	28.2 (2)— hyperlactatemia	0.96 (0.31)—hyperlactatemia	Death/MV duration/IVH/PDA/ROP/BPD
Tuten A [51]	2017	Turkey	РС	Preterm	60	27 (2.5)	0.99 (0.28)	Death/BPD/PDA/NEC/IVH/ROP
Deshpande SA [52]	1996	UK	РС	All mechanically ventilated	75	29 (23–40)	1.3 (0.55–4.08)	Death
Chilinda GK [53]	2018	Malawi	РС	All	389	-	2.9 (0.57)—hyperlactatemia	Death

Author	Year	Country	Study Type	Subgroup Population	No. Patients	Gestational Age	Birth Weight (kg)	Outcomes
Haiju Z [54]	2008	China	РС	Birth Asphyxia	18	38.1 (1.05)–moderate to severe HIE	2.7 (2.2–3.1)—moderate to severe HIE	Severe HIE
Neacsu A [55]	2020	Romania	RC	Birth Asphyxia	274	Term infants (>37 weeks)	-	APGAR < 3 first minute OR APGAR < 5 fifth minute OR respiratory insufficiency OR NICU > 24 h
Mazouri A [56]	2021	Iran	РС	Meconium Aspirate Syndrome	150	38.6 (1.43)	-	Pulmonary hemorrhage/pulmonary hypertension/IVH/MV necessity
Syed F [57]	2019	India	PC	Preterm	156	34–36 + 6/7 weeks	-	RDS/TTN/pneumonia/MAS
Karabayir N [58]	2014	Turkey	PC	All	1341	39.3 (0.9)	3.4 (0.6)	MAS/MV/O2 supply
Ozkiraz S [59]	2013	Turkey	CC	TTN	56	37.7 (1.6)	2.9 (0.5)	Respiratory support
Simovic AM [60]	2016	Serbia	CC	Preterm	108	31.7 (3.3)—respiratory support	1.8 (0.7)	Respiratory support
Miletin J [61]	2008	Ireland	РС	Preterm	38	26.5 (24–29)—low SVC group	1.1 (0.5–1.44)—Low SVC group	Low SVC
Balushi AA [62]	2017	Canada	RC	Birth Asphyxia	190	39.2 (1.5)—hypotension group	3.4 (0.6)—Hypotension group	Hypotension/brain injury

PC: Prospective cohort; RC: retrospective cohort; CC: case–control; CHD: congenital heart disease; NEC: necrotizing enterocolitis; GI: gastrointestinal; MV: mechanical ventilation; IVH: intraventricular hemorrhage; PDA: persistent ductus arteriosus; ROP: retinopathy of prematurity; BPD: bronchopulmonary dysplasia; HIE: hypoxic-ischemic encephalopathy; NICU: neonatal intensive care unit; RDS: respiratory distress syndrome; TTN: transient tachypnea of the newborn; MAS: meconium aspirate syndrome; SVC: superior vena cava flow.

		irvivors			-survivo			Std. Mean Difference	Std. Mean Difference
Study or Subgroup	Mean		Total	Mean	SD	Total	Weight	IV, Random, 95% CI	IV, Random, 95% CI
1.5.1 Congenital Hea	rt Disea	se							
Amirnovin R 2013	4.1	2.1	20	6.5	2.3	4	2.7%	-1.09 [-2.21, 0.04]	
Charpie JR 2000	5.6	2.1	37	9.4	3.8	9	3.1%	-1.50 [-2.29, -0.70]	
Cheung PY 2005	6.5	3.7	43	15.8	8.9	14	3.3%	-1.70 [-2.38, -1.01]	
Christmann M 2018	5.93	11.05	35	10.1	18.54	22	3.4%	-0.29 [-0.82, 0.25]	
Joffe AR 2007	7	4	51	12	18	19	3.4%	-0.50 [-1.03, 0.03]	
Liu X 2020	1.5	1.5	177	2.2	1.8	30	3.5%	-0.45 [-0.84, -0.06]	
Miyamoto T 2008	3.88	1.52	26	6.7	4.08	8	3.1%	-1.18 [-2.03, -0.33]	
Photiadis J 2006	2.4	0.1	21	9.8	2	5		-8.72 [-11.47, -5.97]	4
Rocha TS 2010	6.63	4.11	52	6.73	3.78	24	3.4%	-0.02 [-0.51, 0.46]	
Shuhaiber J 2012		19.47	56		15.9	56	3.5%	-0.01 [-0.38, 0.36]	
Verheijen PM 2010	6.2	0.58	107	4.61	1.18	10	3.2%	2.44 [1.72, 3.16]	
Subtotal (95% CI)	0.2	0.58	625	4.01	1.10	201	33.9%	-0.72 [-1.38, -0.06]	
	1 07 0			16 10					
Heterogeneity: Tau ² =				df = 10	(P < 0.0)0001);	$1^{2} = 92\%$		
Test for overall effect	Z = 2.1	4 (P = 0)	0.03)						
1.5.2 Birth Asphyxia			21		100000000	10101	12.122		
Araki S 2010	17.11	4.03		23.42	3.55	11	2.6%	-1.62 [-2.85, -0.38]	
Hayakawa M 2014	9.7	7.75		11.76	8.84	135	3.6%	-0.24 [-0.51, 0.02]	
Li J 2012	9.4	4	11	10.4	3.3	10	3.1%	-0.26 [-1.12, 0.60]	
Manotas H 2017	3.1	2.6	60	13	9.9	4	2.7%	-2.93 [-4.06, -1.79]	
Polackova R 2017	9.1	5.75	34	15.75	5.93	17	3.3%	-1.13 [-1.75, -0.50]	
Tokuhisa T 2014	10.6	5	8	13.8	5.8	15	3.0%	-0.56 [-1.43, 0.32]	
Subtotal (95% CI)			210			192	18.3%	-1.01 [-1.71, -0.32]	•
Heterogeneity: Tau ² =	0.57; C	$hi^2 = 28$	3.25. d	f = 5 (P)	< 0.000	(1); $I^2 =$	82%		
Test for overall effect				2,000					
1.5.3 ECMO									
Buijs EAB 2014	1.9	0.15	38	1.83	0.08	18	3.4%	0.52 [-0.05, 1.09]	
Cheung PY 1994	13.7	6.32	21		9.2	7	2.5%	-3.38 [-4.67, -2.10]	
Cheung PY 2002	15.7	5	22		17.2	15	3.2%	-1.05 [-1.75, -0.35]	
Grayck EN 1995	7.8	0.8	72		3.3	10	2.8%	-5.18 [-6.23, -4.13]	<u></u>
Howard TS 2016	3.6	1.68	42	5.9	4.91	42	3.5%	-0.62 [-1.06, -0.18]	
Subtotal (95% CI)	5.0	1.00	195	5.9	4.91	92	15.4%	-1.87 [-3.47, -0.27]	
Heterogeneity: $Tau^2 =$	2 15. 0	L:2 1/		JE 4 (1.07 [3.47, 0.27]	
				af = 4 (P < 0.00	001); 1	= 96%		
Test for overall effect	L = 2.2	9(P = 0	1.02)						
1.5.4 Preterm									
							10.000		
Abubacker M 2002	1.2	1.7	15		10.45	5	2.8%	-0.65 [-1.69, 0.39]	
Groenendaal F 2003	3.9	2.8	66		9.1	13	3.3%	-1.57 [-2.21, -0.92]	
Kessler U 2006	2.6	0.25	81	7	1.8	23	3.1%	-5.05 [-5.89, -4.21]	←
Matsushita FY 2019	6.8	3.9	51	9.4	4.85	29	3.5%	-0.60 [-1.07, -0.14]	
Phillips LA 2011	7.49	13.17	334	10.89	14.45	47	3.6%	-0.25 [-0.56, 0.05]	
Reppucci ML 2020	1.93	1.32	31	5.96	6.7	11	3.2%	-1.12 [-1.85, -0.38]	
Subtotal (95% CI)			578			128	19.4%	-1.52 [-2.67, -0.37]	
Heterogeneity: Tau ² =	1.93; C	$hi^2 = 11$	17.27,	df = 5 (P < 0.00	0001); I	$^{2} = 96\%$		
Test for overall effect									
1.5.5 Term									
Chen D 2020	7.9	1.96	42	11.14	3.73	25	3.4%	-1.16 [-1.70, -0.63]	
	3.9	3.7	133	5.6	4.3	79	3.6%	-0.43 [-0.71, -0.15]	
	4.66	5.58	34	9.01	9.88	16	3.3%	-0.59 [-1.20, 0.01]	
Erdeve O 2019		1.4	54	8.73	9.88	16	2.6%	-1.03 [-2.26, 0.21]	
Erdeve O 2019 Lekhwani S 2010	2 04	1.4	215	0.73	0.59	126		-0.72 [-1.11, -0.32]	
Erdeve O 2019 Lekhwani S 2010 Ouellete C 2019	2.04		213					-0.72 [-1.11, -0.32]	–
Erdeve O 2019 Lekhwani S 2010 Ouellete C 2019 Subtotal (95% CI)		1.2 5	10						
Erdeve O 2019 Lekhwani S 2010 Ouellete C 2019 Subtotal (95% CI) Heterogeneity: Tau ² =	= 0.08; C				= 0.11);	= 51	70		
Erdeve O 2019 Lekhwani S 2010 Ouellete C 2019 Subtotal (95% CI)	= 0.08; C				= 0.11);	1 = 51	70		
Erdeve O 2019 Lekhwani S 2010 Ouellete C 2019 Subtotal (95% CI) Heterogeneity: Tau ² = Test for overall effect	= 0.08; C		.0004		= 0.11);				
Erdeve O 2019 Lekhwani S 2010 Ouellete C 2019 Subtotal (95% CI) Heterogeneity: Tau ² = Test for overall effect Total (95% CI)	= 0.08; C : Z = 3.5	4 (P = 0	1823			739	100.0%	-1.09 [-1.46, -0.73]	•
Erdeve O 2019 Lekhwani S 2010 Ouellete C 2019 Subtotal (95% CI) Heterogeneity: Tau ² = Test for overall effect Total (95% CI)	= 0.08; C : Z = 3.5	4 (P = 0	1823			739	100.0%		· · · · · · · · · · · · · · · · · · ·
Erdeve O 2019 Lekhwani S 2010 Ouellete C 2019 Subtotal (95% CI) Heterogeneity: Tau ² = Test for overall effect	= 0.08; C : Z = 3.5 = 0.96; C	4 (P = 0) thi ² = 40	1823 12.42,) df = 31		739	100.0%		-4 -2 0 2 4 Favors lower lactate Favors higher lactate


Figure 2. Meta-analysis of hyperlactatemia (continuous variable) and mortality stratified by neonatal population [15–46].

We identified 12 studies evaluating hyperlactatemia as a dichotomous variable and its association with mortality, comprising 1801 patients. Hyperlactatemia was associated with a higher risk of mortality (OR, 9.39 [95% CI, 4.13–21.35]; $I^2 = 76\%$; p < 0.00001) (Figure 4).

the day of the laws		rvivors			surviv			Std. Mean Difference	Std. Mean Difference
study or Subgroup	Mean		Total	Mean	SD	Total	Weight	IV, Random, 95% CI	IV, Random, 95% CI
1.9.1 Early lactate (<				2020 1012		10.0	12 12 12 12		
Araki S 2010	17.11			23.42	3.55	11	2.6%	-1.62 [-2.85, -0.38]	
Chen D 2020	7.9	1.96		11.14	3.73	25	3.4%	-1.16 [-1.70, -0.63]	
Groenendaal F 2003	3.9	2.8	66		9.1	13	3.3%	-1.57 [-2.21, -0.92]	
layakawa M 2014	9.7	7.75		11.76	8.84	135	3.6%	-0.24 [-0.51, 0.02]	~
_i J 2012	9.4	4	11	10.4	3.3	10	3.1%	-0.26 [-1.12, 0.60]	
Manotas H 2017	3.1	2.6	60	13	9.9	4	2.7%	-2.93 [-4.06, -1.79]	
Matsushita FY 2019	6.8	3.9	51		4.85	29	3.5%	-0.61 [-1.07, -0.14]	
Phillips LA 2011		14.63		14.49	19.9	47	3.6%	-0.39 [-0.69, -0.08]	
Polackova R 2017	9.1	5.75		15.75	5.93	17	3.3%	-1.13 [-1.75, -0.50]	
Tokuhisa T 2014	10.6	5	8	13.8	5.8	15	3.0%	-0.56 [-1.43, 0.32]	
Subtotal (95% CI)			703			306	32.0%	-0.92 [-1.31, -0.53]	◆
Heterogeneity: Tau ² =	0.27; C	$hi^2 = 43$	3.58, df	f = 9 (P)	< 0.00	001); I ²	= 79%		
Test for overall effect:	Z = 4.6	5 (P < 0	0.00001	L)					
1.9.2 Late lactate (>3	days o	f life)							
Abubacker M 2002	1.2	1.7	15	4.7	10.45	5	2.8%	-0.65 [-1.69, 0.39]	
Amirnovin R 2013	4.1	2.1	20	6.5	2.3	4	2.7%	-1.09 [-2.21, 0.04]	
Buijs EAB 2014	1.9	0.15	38	1.83	0.08	18	3.4%	0.52 [-0.05, 1.09]	
Charpie JR 2000	5.6	2.1	37	9.4	3.8	9	3.1%	-1.50 [-2.29, -0.70]	
Cheung PY 1994	13.7	6.32	21	38.4	9.2	7	2.5%	-3.38 [-4.67, -2.10]	
Cheung PY 2002	9	5	22	21.4	17.2	15	3.2%	-1.05 [-1.75, -0.35]	
Cheung PY 2005	6.5	3.7	43	15.8	8.9	14	3.3%	-1.70 [-2.38, -1.01]	
Christmann M 2018	5.93	11.05	35	10.1	18.54	22	3.4%	-0.29 [-0.82, 0.25]	
Erdeve O 2019	3.9	3.7	133	5.6	4.3	79	3.6%	-0.43 [-0.71, -0.15]	
Grayck EN 1995	7.8	0.8	72	14.8	3.3	10	2.8%	-5.18 [-6.23, -4.13]	<u>←</u>
Howard TS 2016	3.6	1.68	42	5.9	4.91	42	3.5%	-0.62 [-1.06, -0.18]	
offe AR 2007	7	4	51	12	18	19	3.4%	-0.50 [-1.03, 0.03]	
Kessler U 2006	2.6	0.25	81	7	1.8	23	3.1%	-5.05 [-5.89, -4.21]	←
Lekhwani S 2010	4.66	5.58	34	9.01	9.88	16	3.3%	-0.59 [-1.20, 0.01]	
Liu X 2020	1.5	1.5	177	2.2	1.8	30	3.5%	-0.45 [-0.84, -0.06]	
Miyamoto T 2008	3.88	1.52	26	6.7	4.08	8	3.1%	-1.18 [-2.03, -0.33]	
Duellete C 2019	2.04	1.4	6	8.73	8.39	6	2.6%	-1.03 [-2.26, 0.21]	
Photiadis J 2006	2.4	0.1	21	9.8	2	5		-8.72 [-11.47, -5.97]	4
Reppucci ML 2020	1.93	1.32	31	5.96	6.7	11	3.2%	-1.12 [-1.85, -0.38]	
Rocha TS 2010	6.63	4.11	52	6.73	3.78	24	3.4%	-0.02 [-0.51, 0.46]	
Shuhaiber J 2012		19.47	56	11.7	15.9	56	3.5%	-0.01 [-0.38, 0.36]	
Verheijen PM 2010	6.2		107		1.18	10	3.2%	2.44 [1.72, 3.16]	
Subtotal (95% CI)	0.2	0.50	1120	4.01	1.10	433		-1.20 [-1.74, -0.67]	
Heterogeneity: $Tau^2 =$	1 47.0	hi ² - 20		lf - 21	(P < 0				•
Test for overall effect:					(F < 0.)	,0001);	1 = 94%		
rest for overall effect:	2 = 4.5	0 (r < 0							
Total (95% CI)			1823			730	100.0%	-1.10 [-1.46, -0.73]	
Heterogeneity: Tau ² =	0.06.0	hi ² - 20		IF _ 21	(D < C			1.10 [-1.40, -0.75]	
					(P < 0.)	,0001);	1 = 92%		-4 -2 0 2 4
Test for overall effect:				l) df = 1 (F					Favors lower lactate Favors higher lactate

Figure 3. Meta-analysis of hyperlactatemia (continuous variable) and mortality stratified by time of lactate assessment (early vs. late) [15–46].

	Hyperlacta		No Hyperlact			Odds Ratio	Odds Ratio
Study or Subgroup	Events	Total	Events	Total	Weight	IV, Random, 95% CI	IV, Random, 95% Cl
1.10.1 Lactate > 4mmoL/L							
Fernandez HGC 2012	8	60	1	96	6.7%	14.62 [1.78, 120.09]	· · · · · · · · · · · · · · · · · · ·
Márquez-González H 2015	20	53	2	101	8.6%	30.00 [6.65, 135.26]	
Márquez-González H-2 2015	34	80	10	147	10.9%	10.13 [4.64, 22.09]	
Matsushita FY 2019	52	60	9	12	8.6%	2.17 [0.48, 9.75]	
Murtuza B 2011	13	28	13	193	10.4%	12.00 [4.73, 30.47]	
Okur N 2018	10	34	11	85	10.3%	2.80 [1.06, 7.41]	
Tuten A 2017 Subtotal (95% CI)	5	22 337	11	38 672	9.5% 65.0%	0.72 [0.21, 2.44] 5.61 [2.27, 13.84]	
Total events	142		57				
Heterogeneity: Tau ² = 1.06; Chi	$^{2} = 24.63, d$	f = 6 (P)	= 0.0004); I ² =	= 76%			
Test for overall effect: Z = 3.74	(P = 0.0002))					
1.10.2 Lactate > 5mmoL/L							
Deshpande SA 1996 Subtotal (95% CI)	4	7 7	10	68 68	8.1% 8.1%	7.73 [1.50, 39.89] 7.73 [1.50, 39.89]	
Total events	4		10				
Heterogeneity: Not applicable							
Test for overall effect: $Z = 2.44$	(P = 0.01)						
1.10.3 Lactate > 6mmoL/L							
Murtuza B 2011 Subtotal (95% CI)	11	12 12	24	209 209	6.8% 6.8%		
Total events	11		24				
Heterogeneity: Not applicable							
Test for overall effect: $Z = 4.16$	(P < 0.0001)					
1.10.4 Lactate > 7mmoL/L							
Howard TS 2016 Subtotal (95% CI)	18	21 21	24	63 63	9.2% 9.2%	9.75 [2.59, 36.64] 9.75 [2.59, 36.64]	
Total events	18		24				
Heterogeneity: Not applicable							
Test for overall effect: Z = 3.37	(P = 0.0007))					
1.10.5 Lactate > 12mmoL/L							
Chilinda GK 2018	5	6	1	383		1910.00 [104.17, 35020.33]	
Tokuhisa T 2014	5	6	10	17	6.1%	3.50 [0.33, 36.86]	
Subtotal (95% CI)		12		400	10.9%	76.98 [0.16, 36987.76]	
Total events	10		11				
Heterogeneity: Tau ² = 18.04; Cl Test for overall effect: Z = 1.38		df = 1 (F	$P = 0.0010$; I^2	= 91%			
Total (95% CI)		389		1412	100.0%	9.39 [4.13, 21.35]	-
Total events	185		126				
Heterogeneity: $Tau^2 = 1.46$; Chi		f = 11 (F)		$^{2} = 76\%$			0.005 0.1 1 10 2
Test for overall effect: $Z = 5.34$							0.005 0.1 1 10 24 Favors Hyperlactatemia Favors No Hyperlactatemia
Test for subgroup differences: C	"hi2 - E 00	df _ 4 (0	- 0 20) 12 -	22 20/			ravors nyperiactatenna Favors No Hyperiactatenna



Adverse Outcomes

Hyperlactatemia is also associated with a higher risk of acute kidney injury (SMD, -0.68 [95% CI, -0.98 to -0.38]; I² = 50%; n = 453; p < 0.00001), a higher risk of requiring renal replacement therapy in neonates with congenital heart disease (SMD, -0.84 [95% CI, -1.41 to -0.26]; I² = 44%; n = 153; p = 0.004) (Figure S2), and worse neurological outcomes in neonates with birth asphyxia (SMD, -0.44 [95% CI, -0.67 to -0.22]; I² = 0%; n = 307; p = 0.0001) (Figure S3).

Hyperlactatemia is not associated with a higher risk of respiratory morbidities, bronchopulmonary dysplasia (BPD), persistent ductus arteriosus (PDA), intraventricular hemorrhage (IVH), or retinopathy of prematurity (ROP) (Figures S4–S9).

However, higher lactate levels from umbilical cord blood are associated with a higher risk of worse outcomes (Figure S10).

3.2. Data Accuracy Test for Adverse Outcomes

The estimate of sensitivity was 0.769 (95% CI, 0.692–0.831), and that of specificity was 0.791 (95% CI, 0.718–0.850). We observed a high heterogeneity among the studies, with a wide variety of sensitivity and specificity estimates. The prevalence rates of adverse outcomes ranged widely from 0.18% to 75%. We then applied the DTA estimates for sensitivity (0.769) and specificity (0.791) from our meta-analysis to a hypothetical cohort of 10,000 neonates with a prevalence rate of adverse outcomes of 0.18% (resulting in a median of 4.15 cases of adverse outcomes being missed and 2086 cases being wrongly diagnosed as an adverse outcome), 15% (resulting in a median of 346 cases of adverse outcomes being missed and 1045 cases being wrongly diagnosed as an adverse outcome), and 75% (resulting in a median of 1732 cases of adverse outcomes being missed and 522 being wrongly diagnosed as an adverse outcome). Summary receiver operating characteristic curves and forest plots are presented in Figure S11 and Figure 5, respectively. We applied the QUADAS-2 tool to assess the quality of studies, and the risk of bias was low (Figure S12).

Study	ТР	FP	FN	TN	Sensitivity (95% CI)	Specificity (95% CI)	Sensitivity (95% CI)	Specificity (95% CI)
			1000					specificity (55% cl)
Westgren M 1995	3	196	4	3729	0.43 [0.10, 0.82]	0.95 [0.94, 0.96]	-	
Ozkiraz S 2013	23	3	19	11	0.55 [0.39, 0.70]	0.79 [0.49, 0.95]		
Groenendaal F 2003	8	9	5	57	0.62 [0.32, 0.86]	0.86 [0.76, 0.94]		
de Bernardo G 2020	26	60	12	254	0.68 [0.51, 0.82]	0.81 [0.76, 0.85]		-
White CRH 2012	29	2537	12	18604	0.71 [0.54, 0.84]	0.88 [0.88, 0.88]		
Simovic A 2015	28	32	10	91	0.74 [0.57, 0.87]	0.74 [0.65, 0.81]		
Beken S 2014	26	14	9	9	0.74 [0.57, 0.88]	0.39 [0.20, 0.61]		
Hussain F 2008	31	80	10	98	0.76 [0.60, 0.88]	0.55 [0.47, 0.63]		
Phillips LA 2011	36	73	11	261	0.77 [0.62, 0.88]	0.78 [0.73, 0.82]		-
Tuuli MG 2014	47	1262	9	3592	0.84 [0.72, 0.92]	0.74 [0.73, 0.75]		
Tuuli MG 2016	74	1983	14	5643	0.84 [0.75, 0.91]	0.74 [0.73, 0.75]		
Neacsu A 2020	108	25	16	125	0.87 [0.80, 0.92]	0.83 [0.76, 0.89]	-	-
Mazouri A 2021	30	35	0	85	1.00 [0.88, 1.00]	0.71 [0.62, 0.79]		
Nadeem M 2010	5	10	0	57	1.00 [0.48, 1.00]	0.85 [0.74, 0.93]	0 0.2 0.4 0.6 0.8 1	

Figure 5. Forest plots of the sensitivity and specificity of lactate for adverse outcomes in neonates [33, 36,55,56,59,63–71].

4. Discussion

This systematic review and meta-analysis support the hypothesis that higher lactate levels are associated with increased mortality and risk of morbidities (AKI, RRT necessity, respiratory complications, hemodynamic instability, and neurological deficit) in neonates. This observation was similar across different subgroups of patients, from preterm infants to neonates with birth asphyxia. Although the data are robust and consistent, their interpretation is complicated due to the heterogeneity between studies, with different conditions and times of assessment. Indeed, the included studies had heterogeneity as high as 95%, even after subgrouping into more homogeneous groups, explaining the wide range of sensitivity

(43–100%) and specificity (39–95%) in the data accuracy test for adverse outcomes. Using the estimated sensitivity (0.769) and specificity (0.791) and assuming a prevalence of 15% for adverse outcomes (the median of prevalence among studies) in a hypothetical cohort of 10,000 neonates, assessing lactate level alone would miss 346 cases (false negative) and wrongly diagnose 1776 cases (false positive).

Lactate is a widely used marker of altered tissue perfusion in critically ill patients, especially in adults, where hyperlactatemia is an indispensable feature that can be used to evaluate shock state. However, altered blood lactate cannot be attributed exclusively to anaerobic metabolism [72]. Other physiopathology mechanisms, including glycolysis, catecholamines release, liver hypoperfusion, and alterations in pyruvate dehydronegase activity (through mitochondrial dysfunction [73]) can contribute to an elevated lactate concentration [74]. Consequently, trying to define a cut-off for hyperlactatemia is difficult, unless the clinical condition and time of assessment are well determined. For instance, our meta-analysis showed that a lactate level greater than 4 mmoL/L was associated with higher mortality (OR, 5.61 [95% CI, 2.27–13.84]; $I^2 = 76\%$; n = 1009; p = 0.0002). However, when analyzing lactate as a continuous variable, we found 20 studies where the survivor group had a mean lactate level greater than 4 mmoL/L. Still, an elevated lactate level should always be a warning signal that requires evaluation [1]. Jansen TC et al. demonstrated that in adults, with increasing initial lactate levels, survival quickly decreased [75].

Therefore, without a clear neonatal subpopulation, clinical condition, and time of assessment, the lactate level alone is unlikely to assist as a screening test for adverse outcomes in newborns. However, as the neonates with the highest risk of death were those with a higher lactate concentration, lactate levels could be used to stratify those with a higher risk of adverse outcomes. These interpretations are in agreement with pediatric studies. Scott HF et al. [4], found that in children attending emergency departments, hyperlactatemia is associated with mortality, but with low sensitivity (20%). That is, lactate levels alone are not effective as a screening test, but might be used to identify the patients at highest risk. The evidence that lactate is a marker of severity of illness in adults is vast [73]. In fact, the SEPSIS-3 consensus requires a persistence of lactate greater than 2 mmoL/L to identify adult patients with sepsis with a greater risk of mortality [76]. For this reason, recent studies in adult and pediatric populations have focused on lactate clearance as the predictor of outcome, rather than the isolated lactate level itself [74,77–79]. In a recent systematic review evaluating adult patients, Jean-Louis Vincent et al. found that serial lactate measurement could be useful in the evaluation of the response to therapy in critically ill patients and stated that lactate clearance evaluation seems to be valid regardless of the initial value [74]. Despite the complexity of the interpretation of lactate level, its decrease is ultimately a good sign [80].

Future studies evaluating lactate levels in neonates need to adjust for potential confounders in lactate metabolism. For example, we did not find any study evaluating a possible interference of vasoactive drugs in lactate metabolism. It is known that the use of exogenous catecholamines induces an increased plasma lactate concentration [81]. Moreover, with recently published guidelines using point-of-care ultrasound to assess the hemodynamic state in neonates [82], lactate could be an additional parameter in conjunction with an echocardiogram.

Our systematic review and meta-analysis were conducted through a rigorous search strategy through all of the available literature, including four studies not written in English, with strong statistical analysis, and risk of bias assessment. However, several limitations are worthy of note. First, a meta-analysis of observational studies does not permit conclusions about causality. Second, we found a wide heterogeneity between studies, with varied subpopulations, clinical conditions, and lack of adjustment for covariates. This heterogeneity poses a challenge in determining whether the outcomes and studies are comparable or not. With our results, we suggest that further research evaluating blood lactate levels carefully adjust for potential confounders, including exogenous catecholamines administration. Moreover, research efforts should focus on inspecting serial lactate measurements, rather than a single measurement. Third, as there is no definition of hyperlactatemia in neonates, we found no study where the threshold was predefined in the data accuracy test analysis. Lastly, 13 of the included studies had a fair quality classification through the Newcastle-Ottawa Scale.

5. Conclusions

Our systematic review and meta-analysis, which included data from 46,069 neonates, suggest that greater lactate levels are associated with a higher risk of mortality and morbidities. Nonetheless, until new studies assess the precise clinical condition and time of assessment, the results from our meta-analysis do not support the use of lactate levels as a screening test to identify adverse outcome in newborns. Research efforts should focus on analyzing serial lactate measurements, rather than a single measurement.

Supplementary Materials: The following supporting information can be downloaded at: https: //www.mdpi.com/article/10.3390/children10111796/s1, Figure S1: Search Strategy; Figure S2: Meta-analysis of hyperlactatemia (Continuous Exposure) and Acute Kidney Injury/RRT necessity; Figure S3: Meta-analysis of hyperlactatemia (Continuous Exposure) in the first 24 hours of life in neonates with birth asphyxia and Neurological Outcomes; Figure S4: Meta-analysis of hyperlactatemia (Continuous Exposure) and Respiratory morbidities; Figure S5: Meta-analysis of hyperlactatemia > 4 mmoL/L (Dichotomous Exposure) and risk of Bronchopulmonary Dysplasia; Figure S6: Meta-analysis of hyperlactatemia (Continuous Exposure) and Hemodynamic Instability; Figure S7: Meta-analysis of hyperlactatemia > 4 mmoL/L (Dichotomous Exposure) and risk of Persistent Ductus Arteriosus; Figure S8: Meta-analysis of hyperlactatemia > 4 mmoL/L (Dichotomous Exposure) and risk of Intraventricular Hemorrhage; Figure S9: Meta-analysis of hyperlactatemia > 4 mmoL/L (Dichotomous Exposure) and risk of Retinopathy of Prematurity (ROP); Figure S10: Meta-analysis of hyperlactatemia (Continuous Exposure) from umbilical cord and Adverse Outcomes; Figure S11: Summary Receiver Operating Characteristics (SROC) plot of lactate for adverse outcomes; Figure S12: Summary of Risk of Bias using QUADAS-2 tool; Table S1: Characteristics of the DTA included studies in the systematic review; Table S2: Studies excluded from the meta-analysis with reason; Table S3: Assessment of risk of bias (Newcastle-Ottawa Scale). References [83–204] are cited in the supplementary materials.

Author Contributions: F.Y.M. conceptualized and designed the study, collected data, carried out the initial analyses, drafted the initial manuscript, and reviewed and revised the manuscript. V.L.J.K. conceptualized and designed the study, designed the data collection instruments, collected data, and reviewed and revised the manuscript W.B.D.C. conceptualized and designed the study, coordinated and supervised data collection, and critically reviewed the manuscript for important intellectual content. All authors have read and agreed to the published version of the manuscript.

Funding: This research received no external funding.

Institutional Review Board Statement: Not applicable.

Informed Consent Statement: Not applicable.

Data Availability Statement: Data are contained within the article and supplementary materials.

Conflicts of Interest: The authors declare no conflict of interest.

Abbreviations

CHD Congenital heart disease Confidence interval CI Neonatal intensive care unit NICU OR Odds ratio RRT Renal replacement therapy SD Standard deviation SMD Standard mean deviation Wk Weeks

References

- 1. Bakker, J.; Postelnicu, R.; Mukherjee, V. Lactate: Where Are We Now? Crit. Care Clin. 2020, 36, 115–124. [CrossRef] [PubMed]
- 2. Levy, B. Lactate and shock state: The metabolic view. Curr. Opin. Crit. Care 2006, 12, 315–321. [CrossRef] [PubMed]
- Mikkelsen, M.E.; Miltiades, A.N.; Gaieski, D.F.; Goyal, M.; Fuchs, B.D.; Shah, C.V.; Bellamy, S.L.; Christie, J.D. Serum lactate is associated with mortality in severe sepsis independent of organ failure and shock. *Crit. Care Med.* 2009, 37, 1670–1677. [CrossRef] [PubMed]
- 4. Scott, H.F.; Brou, L.; Deakyne, S.J.; Kempe, A.; Fairclough, D.L.; Bajaj, L. Association between early lactate levels and 30-day mortality in clinically suspected sepsis in children. *JAMA Pediatr.* **2017**, *171*, 249–255. [CrossRef]
- 5. Noori, S.; Seri, I. Evidence-based versus pathophysiology-based approach to diagnosis and treatment of neonatal cardiovascular compromise. *Semin. Fetal Neonatal Med.* **2015**, *20*, 238–245. [CrossRef] [PubMed]
- 6. Matsushita, F.Y.; Krebs, V.L.J.; de Carvalho, W.B. Neonatal Hypotension: What Is the Efficacy of Each Anti-Hypotensive Intervention? A Systematic Review. *Curr. Treat. Options Pediatr.* **2019**, *5*, 406–416. [CrossRef]
- Shamseer, L.; Moher, D.; Clarke, M.; Ghersi, D.; Liberati, A.; Petticrew, M.; Shekelle, P.; Stewart, L.A. Preferred reporting items for systematic review and meta-analysis protocols (prisma-p) 2015: Elaboration and explanation. *BMJ* 2015, 349, 1–25. [CrossRef]
- 8. Higgins, J.; Thomas, J.; Chandler, J.; Cumpston, M.; Li, T.; Page, M.; Welch, V. (Eds.) Cochrane Handbook for Systematic Reviews of Interventions; Version 6; John Wiley & Sons: Chichester, UK, 2021.
- 9. McGowan, J.; Sampson, M.; Salzwedel, D.M.; Cogo, E.; Foerster, V.; Lefebvre, C. PRESS Peer Review of Electronic Search Strategies: 2015 Guideline Statement. *J. Clin. Epidemiol.* **2016**, *75*, 40–46. [CrossRef]
- 10. Ouzzani, M.; Hammady, H.; Fedorowicz, Z.; Elmagarmid, A. Rayyan—A web and mobile app for systematic reviews. *Syst. Rev.* **2016**, *5*, 210. [CrossRef]
- 11. Wells, G.; Shea, B.; O'Connell, D. *The Newcastle-Ottawa Scale (NOS) for Assessing the Quality of Nonrandomised Studies in Meta-Analyses;* The Ottawa Hospital Research Institute: Ottawa, ON, Canada, 2011.
- Whiting, P.F.; Rutjes, A.W.; Westwood, M.E.; Mallett, S.; Deeks, J.J.; Reitsma, J.B.; Leeflang, M.M.; Sterne, J.A.; Bossuyt, P.M.; QUADAS-2 Group. QUADAS-2: A Revised Tool for the Quality Assessment of Diagnostic Accuracy Studies. *Ann. Intern. Med.* 2011, 155, 529–536. [CrossRef]
- 13. Wan, X.; Wang, W.; Liu, J.; Tong, T. Estimating the sample mean and standard deviation from the sample size, median, range and/or interquartile range. *BMC Med. Res. Methodol.* **2014**, *14*, 135. [CrossRef] [PubMed]
- Freeman, S.C.; Kerby, C.R.; Patel, A.; Cooper, N.J.; Quinn, T.; Sutton, A.J. Development of an interactive web-based tool to conduct and interrogate meta-analysis of diagnostic test accuracy studies: MetaDTA. *BMC Med. Res. Methodol.* 2019, 19, 81. [CrossRef] [PubMed]
- 15. Charpie, J.; Dekeon, M.; Goldberg, C.; Mosca, R.; Bove, E.; Kulik, T. Seria blood lactate measurements predict early outcome after neonatal repair or palliation for complex congenital heart disease. *J. Thorac. Cardiovasc. Surg.* 2000, *120*, 73–80. [CrossRef]
- 16. Polackova, R.; Salounova, D.; Kantor, L. Lactate as an early predictor of psychomotor development in neonates with asphyxia receiving therapeutic hypothermia. *Biomed. Pap.* **2018**, *162*, 144–148. [CrossRef] [PubMed]
- 17. Lekhwani, S.; Shanker, V.; Gathwala, G.; Vaswani, N.D. Acid-base disorders in critically ill neonates. *Indian J. Crit. Care Med.* 2010, 14, 65–69. [CrossRef] [PubMed]
- 18. Tokuhisa, T.; Ibara, S.; Minakami, H.; Maede, Y.; Ishihara, C.; Matsui, T. Outcome of infants with hypoxic ischemic encephalopathy treated with brain hypothermia. *J. Obstet. Gynaecol. Res.* **2015**, *41*, 229–237. [CrossRef]
- 19. Matsushita, F.Y.; Krebs, V.J.; De Carvalho, W.B.; Sato, S.A. Hemodynamic instability in the transitional period: A descriptive analysis of extremely low birth weight newborns. *Pediatrics* **2019**, *144*, 642. [CrossRef]
- Buijs, E.A.; Houmes, R.J.; Rizopoulos, D.; Wildschut, E.D.; Reiss, I.K.; Ince, C.; Tibboel, D. Arterial lactate for predicting mortality in children requiring extracorporeal membrane oxygenation. *Minerva Anestesiol.* 2014, 80, 1282–1293.
- 21. Photiadis, J.; Asfour, B.; Sinzobahamvya, N.; Fink, C.; Schindler, E.; Brecher, A.M.; Urban, A.E. Improved hemodynamics and outcome after modified Norwood operation on the beating heart. *Ann. Thorac. Surg.* **2006**, *81*, 976–981. [CrossRef]
- 22. Amirnovin, R.; Keller, R.L.; Herrera, C.; Hsu, J.H.; Datar, S.; Karl, T.R.; Adatia, I.; Oishi, P.; Fineman, J.R. B-type natriuretic peptide levels predict outcomes in infants undergoing cardiac surgery in a lesion-dependent fashion. *J. Thorac. Cardiovasc. Surg.* **2013**, 145, 1279–1287. [CrossRef]
- 23. Li, J.; Funato, M.; Tamai, H.; Wada, H.; Nishihara, M.; Iwamoto, H.; Okazaki, Y.; Shintaku, H. Predictors of neurological outcome in cooled neonates. *Pediatr. Int.* 2013, 55, 169–176. [CrossRef] [PubMed]
- 24. Shuhaiber, J.; Gauvreau, K.; Thiagarjan, R.; Bacha, E.; Mayer, J.; Del Nido, P.; Pigula, F. Congenital heart surgeon's technical proficiency affects neonatal hospital survival. *J. Thorac. Cardiovasc. Surg.* **2012**, *144*, 1119–1124. [CrossRef]
- 25. Hayakawa, M.; Ito, Y.; Saito, S.; Mitsuda, N.; Hosono, S.; Yoda, H.; Cho, K.; Otsuki, K.; Ibara, S.; Terui, K.; et al. Incidence and prediction of outcome in hypoxic-ischemic encephalopathy in Japan. *Pediatr. Int.* **2014**, *56*, 215–221. [PubMed]
- Joffe, A.R.; Robertson, C.M.T.; Nettel-Aguirre, A.; Rebeyka, I.M.; Sauve, R.S. Mortality after neonatal cardiac surgery: Prediction from mean arterial pressure after rewarming in the operating room. *J. Thorac. Cardiovasc. Surg.* 2007, 134, 311–318. [CrossRef] [PubMed]
- 27. Manotas, H.; Troncoso, G.; Sánchez, J.; Molina, G. Description of a cohort of neonatal patients diagnosed with perinatal asphyxia and treated with therapeutic hypothermia. *Perinatol. Reprod. Hum.* **2018**, *32*, 70–77.

- Liu, X.; Hong, H.-F.; Zhang, H.-B.; Xu, Z.-M.; Liu, J.-F.; Zhang, H. Neonatal surgical outcomes after prenatal diagnosis of complex congenital heart disease: Experiences of a perinatal integrated diagnosis and treatment program. *World J. Pediatr.* 2020, 16, 494–501. [CrossRef]
- 29. Ouellette, C.; Mejias, A.; Shimamura, M.; Marzec, L.; Salamon, D.; Leber, A.; Sanchez, P.J. Early predictors of mortality in neonatal disseminated herpes simplex virus infection. *Open Forum Infect. Dis.* **2019**, *6*, S803. [CrossRef]
- 30. Miyamoto, T.; Sinzobahamvya, N.; Photiadis, J.; Brecher, A.M.; Asfour, B. Survival after surgery with cardiopulmonary bypass in low weight patients. *Asian Cardiovasc. Thorac. Ann.* **2008**, *16*, 115–119. [CrossRef]
- 31. Rocha, T.S.; Silveira, A.S.; Botta, A.M.; Ricachinevsky, C.P.; Dalle Mulle, L.; Nogueira, A. Serum lactate as mortality and morbidity marker in infants after Jatene's operation. *Rev. Bras. Cir. Cardiovasc.* **2010**, *25*, 350–358. [CrossRef]
- Howard, T.S.; Kalish, B.T.; Wigmore, D.; Nathan, M.; Kulik, T.J.; Kaza, A.K.; Williams, K.; Thiagarajan, R.R. Association of Extracorporeal Membrane Oxygenation Support Adequacy and Residual Lesions with Outcomes in Neonates Supported after Cardiac Surgery*. *Pediatr. Crit. Care Med.* 2016, 17, 1045–1054. [CrossRef]
- 33. Groenendaal, F.; Lindemans, C.; Uiterwaal, C.; de Vries, L. Early arterial lactate and prediction of outcome in preterm neonates admitted to a neonatal intensive care unit. *Biol. Neonate* 2003, *83*, 171–176. [CrossRef]
- 34. Christmann, M.; Valsangiacomo Büchel, E.; Dave, H.; Klauwer, D.; Cavigelli-Brunner, A. Prognostic value of troponin in infants with hypoplastic left heart syndrome between Stage I and II of palliation. *Ann. Pediatr. Cardiol.* **2018**, *11*, 56–59. [CrossRef]
- 35. Cheung, P.Y.; Finer, N.N. Plasma lactate concentration as a predictor of death in neonates with severe hypoxemia requiring extracorporeal membrane oxygenation. *J. Pediatr.* **1994**, *125*, 763–768. [CrossRef]
- Phillips, L.A.; Dewhurst, C.J.; Yoxall, C.W. The prognostic value of initial blood lactate concentration measurements in very low birthweight infants and their use in development of a new disease severity scoring system. *Arch. Dis. Child. Fetal Neonatal Ed.* 2011, *96*, F275–F280. [CrossRef] [PubMed]
- Kessler, U.; Mungnirandr, A.; Nelle, M.; Nimmo, A.F.; Zachariou, Z.; Berger, S. A simple presurgical necrotizing enterocolitismortality scoring system. J. Perinatol. 2006, 26, 764–768. [CrossRef] [PubMed]
- Abubacker, M.; Yoxall, C.; Lamont, G. Peri-operative blood lactate concentrations in pre-term babies with necrotising enterocolitis. *Eur. J. Pediatr. Surg.* 2003, 13, 35–39. [CrossRef] [PubMed]
- Verheijen, P.; Lisowski, L.; Wassink, S.; Visser, G.; Meijboom, E. Preoperative acidosis and infant development following surgery for congenital heart disease. *Herz* 2010, *35*, 358–363. [CrossRef] [PubMed]
- Araki, S.; Takahashi, D.; Matsui, M.; Saito, R.; Morita, H.; Ishii, M.; Senjyu, A.; Morishita, T.; Takano, S.; Chiba, S.; et al. Brain hypothermia therapy for newborns with severe birth asphyxia: An experience from a single neonatal intensive care unit. *J. UOEH* 2010, 32, 205–211. [CrossRef] [PubMed]
- Erdeve, O.; Okulu, E.; Tunc, G.; Celik, Y.; Kayacan, U.; Cetinkaya, M.; Buyukkale, G.; Ozkan, H.; Koksal, N.; Satar, M.; et al. An observational, prospective, multicenter study on rescue high-frequency oscillatory ventilation in neonates failing with conventional ventilation. *PLoS ONE* 2019, 14, e0217768.
- Chen, D.; Liu, X.; Li, J. Lactate levels and clearance rate in neonates undergoing mechanical ventilation in Tibet. J. Int. Med. Res. 2020, 48, 1–11. [CrossRef] [PubMed]
- Cheung, P.; Etches, P.; Weardon, M.; Reynolds, A.; Finer, N.; Robertson, C. Use of plasma lactate to predict early mortality and adverse outcome after neonatal extracorporeal membrane oxygenation: A prospective cohort in early childhood. *Crit. Care Med.* 2002, *30*, 2135–2139. [CrossRef] [PubMed]
- Cheung, P.; Chui, N.; Joffe, A.; Rebeyka, I.; Robertson, C. Postoperative lactate concentrations predict the outcome of infants aged 6 weeks or less after intracardiac surgery: A cohort follow-up to 18 months. *J. Thorac. Cardiovasc. Surg.* 2005, 130, 837–843. [CrossRef] [PubMed]
- 45. Reppucci, M.L.; Hersh, E.H.; Khetan, P.; Coakley, B.A. Predictors of Mortality Among Very Low Birth Weight Infants With Gastrointestinal Perforation. *Am. Surg.* 2020, *87*, 1463–1467. [CrossRef]
- 46. Grayck, E.; Meliones, J.; Kern, F.; Hansell, D.; Ungerleider, R.; Greeley, W. Elevated serum lactate correlates with intracranial hemorrhage in neonates treated with extracorporeal life support. *Pediatrics* **1995**, *96*, 914–917. [CrossRef] [PubMed]
- 47. Fernandez, H.; Vieira, A.; Barbosa, A. The correlation between plasma lactate concentrations and early neonatal mortality. *Rev. Bras. Ter. Intensiv.* **2012**, *24*, 184–187. [CrossRef]
- Márquez-González, H.; Jiménez-Báez, M.V.; Munoz-Ramirez, C.M.; Yanez-Gutierrez, L.; Huelgas-Plaza, A.C.; Almeida-Gutierrez, E.; Villa-Romero, A.R. Development and validation of the Neonatal Mortality Score-9 Mexico to predict mortality in critically ill neonates. *Arch. Argent Pediatr.* 2015, 113, 213–220.
- 49. Murtuza, B.; Wall, D.; Reinhardt, Z.; Stickley, J.; Stumper, O.; Jones, T.J.; Barron, D.J.; Brawn, W.J. The importance of blood lactate clearance as a predictor of early mortality following the modified Norwood procedure. *Eur. J. Cardio-Thorac. Surg.* **2011**, *40*, 1207–1214. [CrossRef]
- 50. Okur, N.; Tayman, C.; Büyüktiryaki, M.; Kadıoğlu Şimşek, G.; Ozer Bekmez, B.; Altuğ, N. Can lactate levels be used as a marker of patent ductus arteriosus in preterm babies? *J. Clin. Lab. Anal.* **2019**, *33*, 1–5. [CrossRef]
- Tuten, A.; Dincer, E.; Topcuoglu, S.; Sancak, S.; Akar, S.; Hakyemez Toptan, H.; Özalkaya, E.; Gokmen, T.; Ovalı, F.; Karatekin, G. Serum lactate levels and perfusion index: Are these prognostic factors on mortality and morbidity in very low-birth weight infants? *J. Matern. Neonatal Med.* 2017, 30, 1092–1095. [CrossRef] [PubMed]

- 52. Deshpande, S.; Platt, M. Association between blood lactate and acid-base status and mortality in ventilated babies. *Arch. Dis. Child. Fetal Neonatal Ed.* **1997**, *76*, F15–F20. [CrossRef]
- 53. Chilinda, G.K.; Gadama, L.A.; Stones, W. Point-of-care umbilical arterial lactate and newborn outcomes in a low resource setting: Cohort study. *BMC Res. Notes* **2018**, *11*, 477. [CrossRef]
- 54. Haiju, Z.; Suyuan, H.; Xiufang, F.; Lu, Y.; Sun, R. The combined detection of umbilical cord nucleated red blood cells and lactate: Early prediction of neonatal hypoxic ischemic encephalopathy. *J. Perinat. Med.* **2008**, *36*, 240–247. [CrossRef]
- 55. Neacsu, A.; Herghelegiu, C.G.; Voinea, S.; Dimitriu, M.C.T.; Ples, L.; Bohiltea, R.E.; Braila, A.D.; Nastase, L.; Bacalbasa, N.; Chivu, L.I.; et al. Umbilical cord lactate compared with pH as predictors of intrapartum asphyxia. *Exp. Ther. Med.* 2021, 21, 80. [CrossRef] [PubMed]
- Mazouri, A.; Fallah, R.; Saboute, M.; Taherifard, P.; Dehghan, M. The prognostic value of the level of lactate in umbilical cord blood in predicting complications of neonates with meconium aspiration syndrome. *J. Matern. Neonatal Med.* 2021, 34, 1013–1019. [CrossRef] [PubMed]
- 57. Syed, F.; Kini, S.; Lewis, L.E.; Ramesh Bhat, Y.; Purkaystha, J. Prediction of respiratory morbidities in late preterm neonates using cord blood arterial lactate and base excess. *Iran. J. Neonatol.* **2019**, *10*, 71–75.
- Karabayir, N.; Demirel, A.; Bayramoglu, E. Blood lactate level and meconium aspiration syndrome. *Arch. Gynecol. Obstet.* 2015, 291, 849–853. [CrossRef] [PubMed]
- 59. Ozkiraz, S.; Gokmen, Z.; Boke, S.B.; Kilicdag, H.; Ozel, D.; Sert, A. Lactate and lactate dehydrogenase in predicting the severity of transient tachypnea of the newborn. *J. Matern. Neonatal Med.* **2013**, *26*, 1245–1248. [CrossRef]
- 60. Simovic, A.M.; Stojkovic, A.K.; Dejan, J.M.; Savic, D. Is it Possible to Predict Mortality in Preterm Neonates, Based on a Single Troponin I Value at 24 h? *Indian J. Pediatr.* 2016, *83*, 466–467. [CrossRef]
- 61. Miletin, J.; Pichova, K.; Dempsey, E.M. Bedside detection of low systemic flow in the very low birth weight infant on day 1 of life. *Eur. J. Pediatr.* **2009**, *168*, 809–813. [CrossRef]
- 62. Al Balushi, A.; Vargas, S.B.; Maluorni, J.; Sanon, P.N.; Rampakakis, E.; Saint-Martin, C.; Wintermark, P. Hypotension and Brain Injury in Asphyxiated Newborns Treated with Hypothermia. *Am. J. Perinatol.* **2018**, *35*, 31–38. [CrossRef]
- 63. White, C.R.H.; Doherty, D.A.; Henderson, J.J.; Kohan, R.; Newnham, J.P.; Pennell, C.E. Accurate prediction of hypoxic-ischaemic encephalopathy at delivery: A cohort study. *J. Matern. Neonatal Med.* **2012**, *25*, 1653–1659. [CrossRef]
- 64. Tuuli, M.; Stout, M.; Shanks, A.; Odibo, A.; Macones, G.; Cahill, A. Umbilical cord arterial lactate compared with pH for predicting neonatal morbidity at term. *Obstet. Gynecol.* 2014, 124, 756–761. [CrossRef] [PubMed]
- 65. Beken, S.; Aydin, B.; Dilli, D.; Erol, S.; Zenciroğlu, A.; Okumuş, N. Can biochemical markers predict the severity of hypoxicischemic encephalopathy? *Turk. J. Pediatr.* 2014, *56*, 62–68. [PubMed]
- 66. Nadeem, M.; Clarke, A.; Dempsey, E.M. Day 1 serum lactate values in preterm infants less than 32 weeks gestation. *Eur. J. Pediatr.* **2010**, *169*, 667–670. [CrossRef]
- 67. Simovic, A.; Stojkovic, A.; Savic, D.; Milovanovic, D.R. Can a single lactate value predict adverse outcome in critically ill newborn? *Bratisl. Lek. Listy* **2015**, *116*, 591–595. [CrossRef]
- 68. De Bernardo, G.; De Santis, R.; Giordano, M.; Sordino, D.; Buonocore, G.; Perrone, S. Predict respiratory distress syndrome by umbilical cord blood gas analysis in newborns with reassuring Apgar score. *Ital. J. Pediatr.* **2020**, *46*, 1–6. [CrossRef] [PubMed]
- 69. Tuuli, M.; Stout, M.; Macones, G.; Cahill, A. Umbilical Cord Venous Lactate for Predicting Arterial Lactic Acidemia and Neonatal Morbidity at Term. *Obstet. Gynecol.* 2016, 127, 674–680. [CrossRef]
- WestWestgren, M.; Divon, M.; Horal, M.; Ingemarsson, I.; Kublickas, M.; Shimojo, N.; Nordström, L. Routine measurements of umbilical artery lactate levels in the prediction of perinatal outcome. *Am. J. Obstet. Gynecol.* 1995, 173, 1416–1422. [CrossRef] [PubMed]
- 71. Hussain, F.; Gilshenan, K.; Gray, P.H. Does lactate level in the first 12 hours of life predict mortality in extremely premature infants? *J. Paediatr. Child Health* 2009, 45, 263–267. [CrossRef]
- 72. Kraut, J.A.; Madias, N.E. Lactic acidosis. N. Engl. J. Med. 2014, 371, 2309–2319. [CrossRef]
- 73. Hernandez, G.; Bellomo, R.; Bakker, J. The ten pitfalls of lactate clearance in sepsis. *Intensive Care Med.* **2019**, 45, 82–85. [CrossRef]
- 74. Vincent, J.L.; e Silva, A.Q.; Couto, L.; Taccone, F.S. The value of blood lactate kinetics in critically ill patients: A systematic review. *Crit. Care* 2016, 20, 1–14. [CrossRef] [PubMed]
- 75. Jansen, T.C.; van Bommel, J.; Schoonderbeek, F.J.; Sleeswijk Visser, S.J.; van der Klooster, J.M.; Lima, A.P.; Willemsen, S.P.; Bakker, J. Early lactate-guided therapy in intensive care unit patients: A multicenter, open-label, randomized controlled trial. *Am. J. Respir. Crit. Care Med.* 2010, *182*, 752–761. [CrossRef]
- 76. Shankar-Hari, M.; Phillips, G.S.; Levy, M.L.; Seymour, C.W.; Liu, V.X.; Deutschman, C.S.; Angus, D.C.; Rubenfeld, G.D.; Singer, M. Developing a newdefinition and assessing newclinical criteria for Septic shock: For the third international consensus definitions for sepsis and septic shock (sepsis-3). *JAMA J. Am. Med. Assoc.* 2016, 315, 775–787. [CrossRef]
- 77. Scott, H.F.; Brou, L.; Deakyne, S.J.; Fairclough, D.L.; Kempe, A.; Bajaj, L. Lactate Clearance and Normalization and Prolonged Organ Dysfunction in Pediatric Sepsis. *J. Pediatr.* **2016**, *170*, 149–155.e4. [CrossRef] [PubMed]
- 78. Marty, P.; Roquilly, A.; Vallée, F.; Luzi, A.; Ferré, F.; Fourcade, O.; Asehnoune, K.; Minville, V. Lactate clearance for death prediction in severe sepsis or septic shock patients during the first 24 hours in intensive care unit: An observational study. *Ann. Intensive Care* 2013, 3, 1–7. [CrossRef] [PubMed]

- 79. Choudhary, R.; Sitaraman, S.; Choudhary, A. Lactate clearance as the predictor of outcome in pediatric septic shock. *J. Emerg. Trauma Shock* **2017**, *10*, 55–59.
- 80. Vink, E.E.; Bakker, J. Practical Use of Lactate Levels in the Intensive Care. J. Intensive Care Med. 2018, 33, 159–165. [CrossRef]
- 81. Bangash, M.N.; Kong, M.L.; Pearse, R.M. Use of inotropes and vasopressor agents in critically ill patients. *Br. J. Pharmacol.* 2012, 165, 2015–2033. [CrossRef]
- Singh, Y.; Tissot, C.; Fraga, M.V.; Yousef, N.; Cortes, R.G.; Lopez, J.; Sanchez-de-Toledo, J.; Brierley, J.; Colunga, J.M.; Raffaj, D.; et al. International evidence-based guidelines on Point of Care Ultrasound (POCUS) for critically ill neonates and children issued by the POCUS Working Group of the European Society of Paediatric and Neonatal Intensive Care (ESPNIC). *Crit. Care* 2020, 24, 1–16. [CrossRef]
- Atallah, J.; Dinu, I.A.; Joffe, A.R.; Robertson, C.M.T.; Sauve, R.S.; Dyck, J.D.; Ross, D.B.; Rebeyka, I.M. Two-year survival and mental and psychomotor outcomes after the Norwood procedure: An analysis of the modified Blalock-Taussig shunt and right ventricle-to-pulmonary artery shunt surgical eras. *Circulation* 2008, *118*, 1410–1418. [CrossRef]
- 84. Bhat, P.; Hirsch, J.C.; Gelehrter, S.; Cooley, E.; Donohue, J.; King, K.; Gajarski, R.J. Outcomes of infants weighing three kilograms or less requiring extracorporeal membrane oxygenation after cardiac surgery. *Ann. Thorac. Surg.* **2013**, *95*, 656–661. [CrossRef]
- Sivarajan, V.; Penny, D.J.; Filan, P.; Brizard, C.; Shekerdemian, L.S. Impact of antenatal diagnosis of hypoplastic left heart syndrome on the clinical presentation and surgical outcomes: The Australian experience. *J. Paediatr. Child Health* 2009, 45, 112–117. [CrossRef]
- Gupta, P.; King, C.; Benjamin, L.; Goodhart, T.; Robertson, M.J.; Gossett, J.M.; Pesek, G.A.; DasGupta, R. Association of Hematocrit and Red Blood Cell Transfusion with Outcomes in Infants Undergoing Norwood Operation. *Pediatr. Cardiol.* 2015, 36, 1212–1218. [CrossRef]
- Topjian, A.A.; Clark, A.E.; Casper, T.C.; Berger, J.T.; Schleien, C.L.; Dean, J.M.; Moler, F.W. Early lactate elevations following resuscitation from pediatric cardiac arrest are associated with increased mortality. *Pediatr. Crit. Care Med.* 2013, 14, e380–e387. [CrossRef]
- 88. Alves, R.L.; Aragão e Silva, A.L.; Kraychete, N.C.D.C.; Campos, G.O.; Martins, M.D.J.; Módolo, N.S.P. Intraoperative lactate levels and postoperative complications of pediatric cardiac surgery. *Paediatr. Anaesth.* **2012**, *22*, 812–817. [CrossRef] [PubMed]
- 89. Burton, G.; Goot, B.; Da Cruz, E.; Kaufman, J. The use of arginine vasopressin in postoperative norwood patients. *Cardiol. Young* **2010**, *20*, S113.
- 90. Rossi, A.F.; Lopez, L.; Dobrolet, N.; Khan, D.; Bolivar, J. Hyperlactatemia in neonates admitted to the cardiac intensive care unit with critical heart disease. *Neonatology* **2010**, *98*, 212–216. [CrossRef]
- 91. Kuzovlev, A.; Perepelitsa, S. Lactat acidosis-Marker of severity of perinatal hypoxia. Resuscitation 2019, 142, e89-e90. [CrossRef]
- 92. Boutaybi, N.; Steggerda, S.J.; Smits-Wintjens, V.E.H.J.; van Zwet, E.W.; Walther, F.J.; Lopriore, E. Early-onset thrombocytopenia in near-term and term infants with perinatal asphyxia. *Vox Sang.* **2014**, *106*, 361–367. [CrossRef] [PubMed]
- 93. Kumar, N.; Yadav, A. Role of umbilical cord arterial pH and lactate in newborn assessment of term antenatal women with hypertensive disorders of pregnancy. *Clin. Epidemiol. Glob. Health* **2020**, *8*, 927–933. [CrossRef]
- 94. De Azevedo, L.S.N.; Da Silva, A.N.; Oliveira, N.F.; Nogueira, P.C.K.; De Oliveira Iglesias, S.B.; Leite, H.P. Acute kidney injury assessed by prifle score and its relationship with metabolic markers and outcome. *Pediatr. Crit. Care Med.* **2012**, *13*, 620.
- Ali Aydemir, N.; Harmandar, B.; Karaci, A.R.; Erdem, A.; Yurtseven, N.; Sasmazel, A.; Yekeler, I. Randomized comparison between mild and moderate hypothermic cardiopulmonary bypass for neonatal arterial switch operation. *Eur. J. Cardio-Thorac. Surg.* 2012, 41, 581–586. [CrossRef] [PubMed]
- 96. Moustafa, A.A.; Antonios, M.A.M.; Abdellatif, E.M.; Hussain, A.H. Association of lactate/albumin ratio level to organ failure and mortality in severe sepsis in a pediatric intensive care unit in Egypt. *Turk. J. Pediatr.* **2018**, *60*, 691–701. [CrossRef] [PubMed]
- 97. Doherty, D.R.; Parshuram, C.S.; Gaboury, I.; Hoskote, A.; Lacroix, J.; Tucci, M.; Joffe, A.; Choong, K.; Farrell, R.; Bohn, D.J.; et al. Hypothermia therapy after pediatric cardiac arrest. *Circulation* **2009**, *119*, 1492–1500. [CrossRef]
- 98. Dogra, K.; Kaur, G.; Basu, S.; Chawla, D. Red Cell Transfusion Practices in Neonatal Intensive Care Unit: An Experience from Tertiary Care Centre. *Indian J. Hematol. Blood Transfus.* **2018**, *34*, 671–676. [CrossRef]
- 99. Hickok, R.L.; Spaeder, M.C.; Berger, J.T.; Schuette, J.J.; Klugman, D. Postoperative Abdominal NIRS Values Predict Low Cardiac Output Syndrome in Neonates. *World J. Pediatr. Congenit. Heart Surg.* **2016**, *7*, 180–184. [CrossRef]
- 100. Hatherill, M.; McIntyre, A.G.; Wattie, M.; Murdoch, I.A. Early hyperlactataemia in critically ill children. *Intensive Care Med.* 2000, 26, 314–318. [CrossRef]
- 101. Ergün, S.; Yildiz, O.; Güneş, M.; Akdeniz, H.S.; Öztürk, E.; Onan, İ.S.; Güzeltaş, A.; Haydin, S. Use of extracorporeal membrane oxygenation in postcardiotomy pediatric patients: Parameters affecting survival. *Perfusion* **2020**, *35*, 608–620. [CrossRef]
- Durward, A.; Tibby, S.M.; Skellett, S.; Austin, C.; Anderson, D.; Murdoch, I.A. The strong ion gap predicts mortality in children following cardiopulmonary bypass surgery. *Pediatr. Crit. Care Med.* 2005, *6*, 281–285. [CrossRef]
- 103. Scott, H.F.; Donoghue, A.J.; Gaieski, D.F.; Marchese, R.F.; Mistry, R.D. The utility of early lactate testing in undifferentiated pediatric systemic inflammatory response syndrome. *Acad. Emerg. Med.* **2012**, *19*, 1276–1280. [CrossRef] [PubMed]
- 104. Sawyer, T.; Billimoria, Z.; Handley, S.; Smith, K.; Yalon, L.; Brogan, T.V.; Digeronimo, R. Therapeutic Plasma Exchange in Neonatal Septic Shock: A Retrospective Cohort Study. *Am. J. Perinatol.* **2020**, *37*, 962–969. [CrossRef]
- 105. Nazir, M.; Wani, W.; Dar, S.A.; Mir, I.H.; Charoo, B.A.; Ahmad, Q.I.; Wajid, S. Lactate clearance prognosticates outcome in pediatric septic shock during first 24 h of intensive care unit admission. J. Intensive Care Soc. 2019, 20, 290–298. [CrossRef]

- 106. Burkhardt, B.E.U.; Rücker, G.; Stiller, B. Prophylactic milrinone for the prevention of low cardiac output syndrome and mortality in children undergoing surgery for congenital heart disease. *Cochrane Database Syst. Rev.* **2015**, 2015. [CrossRef] [PubMed]
- 107. García-Hernández, J.A.; Benítez-Gómez, I.L.; Martínez-López, A.I.; Praena-Fernández, J.M.; Cano-Franco, J.; Loscertales-Abril, M. Prognostic markers of mortality after congenital heart defect surgery. An. Pediatr. 2012, 77, 366–373. [CrossRef] [PubMed]
- Mackie, A.S.; Alton, G.Y.; Dinu, I.A.; Joffe, A.R.; Roth, S.J.; Newburger, J.W.; Robertson, C.M. Clinical outcome score predicts the need for neurodevelopmental intervention after infant heart surgery. *J. Thorac. Cardiovasc. Surg.* 2013, 145, 1248–1254.e2. [CrossRef]
- Cashen, K.; Reeder, R.; Dalton, H.J.; Berg, R.A.; Shanley, T.P.; Newth, C.J.; Pollack, M.M.; Wessel, D.; Carcillo, J.; Harrison, R.; et al. Functional Status of Neonatal and Pediatric Patients After Extracorporeal Membrane Oxygenation. *Pediatr. Crit. Care Med.* 2017, 18, 561–570. [CrossRef]
- Molina Hazan, V.; Gonen, Y.; Vardi, A.; Keidan, I.; Mishali, D.; Rubinshtein, M.; Yakov, Y.; Paret, G. Blood lactate levels differ significantly between surviving and nonsurviving patients within the same risk-adjusted Classification for Congenital Heart Surgery (RACHS-1) group after pediatric cardiac surgery. *Pediatr. Cardiol.* 2010, *31*, 952–960. [CrossRef]
- Neamtu, M.L.; Dobrota, L. Lactic acidosis: A highly indicator of unfavorable outcome in critically ill children. *Intensive Care Med.* 2013, 39, S176–S177.
- 112. Vari, D.; Behere, S.; Spurrier, E.; Baffa, J. Low-dose prostaglandin e1 for congenital heart disease: Is it time to revisit the dosing guidelines. *J. Am. Coll. Cardiol.* 2019, 73, 600. [CrossRef]
- Botha, P.; Deshpande, S.R.; Wolf, M.; Heard, M.; Alsoufi, B.; Kogon, B.; Kanter, K. Extracorporeal membrane oxygenator support in infants with systemic-pulmonary shunts. J. Thorac. Cardiovasc. Surg. 2016, 152, 912–918. [CrossRef]
- Polimenakos, A.C.; Wojtyla, P.; Smith, P.J.; Rizzo, V.; Nater, M.; El Zein, C.F.; Ilbawi, M.N. Post-cardiotomy extracorporeal cardiopulmonary resuscitation in neonates with complex single ventricle: Analysis of outcomes. *Eur. J. Cardiothorac. Surg.* 2011, 40, 1396–1405; discussion 1405. [CrossRef]
- 115. Rhodes, L.A.; Erwin, W.C.; Borasino, S.; Cleveland, D.C.; Alten, J.A. Central Venous to Arterial Co2 Difference after Cardiac Surgery in Infants and Neonates*. *Pediatr. Crit. Care Med.* **2017**, *18*, 228–233. [CrossRef]
- 116. Castro-Rodríguez, C.O.; Rodríguez-Hernández, L.; de Jesús Estrada-Loza, M.; Herrera-Márquez, J.R.; Gómez-Salvador, M.; Flores-Lujano, J.; Núñez-Enríquez, J.C. Prognostic factors associated with postoperative morbidity in children with isolated ventricular septal defect. *Rev. Med. Inst. Mex. Seguro Soc.* 2015, 53, S324–S335.
- 117. Killinger, J.S.; Hsu, D.T.; Schleien, C.L.; Mosca, R.S.; Hardart, G.E. Children undergoing heart transplant are at increased risk for postoperative vasodilatory shock. *Pediatr. Crit. Care Med.* **2009**, *10*, 335–340. [CrossRef]
- Kalyanaraman, M.; DeCampli, W.M.; Campbell, A.I.; Bhalala, U.; Harmon, T.G.; Sandiford, P.; McMahon, C.K.; Shore, S.; Yeh, T.S. Serial blood lactate levels as a predictor of mortality in children after cardiopulmonary bypass surgery. *Pediatr. Crit. Care Med.* 2008, *9*, 285–288. [CrossRef] [PubMed]
- Schumacher, K.R.; Reichel, R.A.; Vlasic, J.R.; Yu, S.; Donohue, J.; Gajarski, R.J.; Charpie, J.R. Rate of increase in serum lactate level risk-stratifies infants after surgery for congenital heart disease. *J. Thorac. Cardiovasc. Surg.* 2014, 148, 589–595. [CrossRef] [PubMed]
- 120. Kubicki, R.; Grohmann, J.; Siepe, M.; Benk, C.; Humburger, F.; Rensing-Ehl, A.; Stiller, B. Early prediction of capillary leak syndrome in infants after cardiopulmonary bypass. *Eur. J. Cardiothorac. Surg.* **2013**, *44*, 275–281. [CrossRef]
- 121. Kramer, P.; Mommsen, A.; Miera, O.; Photiadis, J.; Berger, F.; Schmitt, K.R.L. Survival and Mid-Term Neurologic Outcome after Extracorporeal Cardiopulmonary Resuscitation in Children. *Pediatr. Crit. Care Med.* **2020**, *21*, e316–e324. [CrossRef] [PubMed]
- 122. Mildh, L.H.; Pettilä, V.; Sairanen, H.I.; Rautiainen, P.H. Cardiac troponin T levels for risk stratification in pediatric open heart surgery. *Ann. Thorac. Surg.* 2006, *82*, 1643–1648. [CrossRef] [PubMed]
- 123. Kanaris, C.; Ramanathan, G.; Pritchard, L.; Stibbards, S. Risk stratification of critically ill children and neonates with acute general surgical pathology requiring stabilisation, transfer to tertiary care facility and factors predicting mortality. *Pediatr. Crit. Care Med.* 2018, 19, 91. [CrossRef]
- PR, A.-S.; Lazo-Cárdenas, C.; Rodríguez-Hernández, L.; Márquez-González, H.; JA, G.-S. Mortality-associated factors in pediatric patients with Blalock-Taussig shunt. *Rev. Med. Inst. Mex. Seguro Soc.* 2014, 52, S62–S67.
- 125. Olshove, V.; Berndsen, N.; Nawathe, P.; Robert, S.; Phillips, A. Acute kidney injury scoring system is a better predictor of increased length compared to inotrope score. *Cardiol. Young* **2017**, *27*, S344.
- Manso, P.; Ferreira, M.; Silva, T.; Turquetto, A.; Caneo, L.; Santos, J.; Amato, L.; Carmona, F. Risk factors for mechanical ventilation time after congenital heart surgery. *Cardiol. Young* 2017, 27, S348–S349.
- 127. Rossi, A.F.; Khan, D.M.; Hannan, R.; Bolivar, J.; Zaidenweber, M.; Burke, R. Goal-directed medical therapy and point-of-care testing improve outcomes after congenital heart surgery. *Intensive Care Med.* **2005**, *31*, 98–104. [CrossRef]
- 128. Dodge-Khatami, J.; Gottschalk, U.; Eulenburg, C.; Wendt, U.; Schnegg, C.; Rebel, M.; Reichenspurner, H.; Dodge-Khatami, A. Prognostic value of perioperative near-infrared spectroscopy during neonatal and infant congenital heart surgery for adverse in-hospital clinical events. *World J. Pediatr. Congenit. Heart Surg.* **2012**, *3*, 221–228. [CrossRef]
- 129. Siegel, L.B.; Dalton, H.J.; Hertzog, J.H.; Hopkins, R.A.; Hannan, R.L.; Hauser, G.J. Initial postoperative serum lactate levels predict survival in children after open heart surgery. *Intensive Care Med.* **1996**, 22, 1418–1423. [CrossRef] [PubMed]

- Rastan, A.J.; Walther, T.; Alam, N.A.; Daehnert, I.; Borger, M.A.; Mohr, F.W.; Janousek, J.; Kostelka, M. Moderate versus deep hypothermia for the arterial switch operation--experience with 100 consecutive patients. *Eur. J. Cardiothorac. Surg.* 2008, 33, 619–625. [CrossRef]
- 131. Ricci, Z.; Garisto, C.; Favia, I.; Vitale, V.; Di Chiara, L.; Cogo, P.E. Levosimendan infusion in newborns after corrective surgery for congenital heart disease: Randomized controlled trial. *Intensive Care Med.* **2012**, *38*, 1198–1204. [CrossRef]
- 132. Scherer, B.; Moser, E.A.S.; Brown, J.W.; Rodefeld, M.D.; Turrentine, M.W.; Mastropietro, C.W. Vasoactive-ventilation-renal score reliably predicts hospital length of stay after surgery for congenital heart disease. *J. Thorac. Cardiovasc. Surg.* **2016**, 152, 1423–1429.e1. [CrossRef]
- Brix, N.; Sellmer, A.; Jensen, M.S.; Pedersen, L.V.; Henriksen, T.B. Predictors for an unsuccessful INtubation-SURfactant-Extubation procedure: A cohort study. *BMC Pediatr.* 2014, 14, 155. [CrossRef]
- 134. Solé, A.; Jordan, I.; Bobillo, S.; Moreno, J.; Balaguer, M.; Hernández-Platero, L.; Segura, S.; Cambra, F.J.; Esteban, E.; Rodríguez-Fanjul, J. Venoarterial extracorporeal membrane oxygenation support for neonatal and pediatric refractory septic shock: More than 15 years of learning. *Eur. J. Pediatr.* 2018, 177, 1191–1200. [CrossRef]
- 135. Schlapbach, L.J.; MacLaren, G.; Festa, M.; Alexander, J.; Erickson, S.; Beca, J.; Slater, A.; Schibler, A.; Pilcher, D.; Millar, J.; et al. Prediction of pediatric sepsis mortality within 1 h of intensive care admission. *Intensive Care Med.* 2017, 43, 1085–1096. [CrossRef] [PubMed]
- 136. Munoz, R.; Laussen, P.C.; Palacio, G.; Zienko, L.; Piercey, G.; Wessel, D.L. Changes in whole blood lactate levels during cardiopulmonary bypass for surgery for congenital cardiac disease: An early indicator of morbidity and mortality. *J. Thorac. Cardiovasc. Surg.* 2000, *119*, 155–162. [CrossRef]
- Nagata, H.; Glick, L.; Lougheed, J.; Grattan, M.; Mondal, T.; Thakur, V.; Schwartz, S.M.; Jaeggi, E. Prenatal Diagnosis of Transposition of the Great Arteries Reduces Postnatal Mortality: A Population-Based Study. *Can. J. Cardiol.* 2020, *36*, 1592–1597. [CrossRef]
- Woods, P.; Halliday, R.; Skowno, J. Utilisation of near infrared spectroscopy (NIRS) in monitoring haemodynamic stability of infants with hypoplastic left heart syndrome (HLHS) in the presurgical setting. J. Paediatr. Child Health 2013, 49, 68–69.
- 139. Garisto, C.; Favia, I.; Ricci, Z.; Chiara, L.D.; Morelli, S.; Giorni, C.; Vitale, V.; Picardo, S.; Di Donato, R.M. Initial single-center experience with levosimendan infusion for perioperative management of univentricular heart with ductal-dependent systemic circulation. *World J. Pediatr. Congenit. Heart Surg.* 2010, *1*, 292–299. [CrossRef]
- 140. Jaeggi, E.; Glick, L.; Lougheed, J.; Mondal, T.; Rosenberg, H.; Thakur, V.; Schwartz, S.; Nagata, H. Prenatal detection of transposition of the great arteries does not reduce mortality and morbidity. *Cardiol. Young* **2016**, *26*, S33.
- 141. Rodríguez-Fanjul, J.; Solé, A.; Bobillo, S.; Moreno, J.; Segura, S.; Esteban, E.; Balaguer, M.; Jordan, I. Extracorporeal membrane oxygenation for refractory septic shock in children: Our institution's results. *Eur. J. Heart Fail.* **2017**, *19*, 23–24.
- Morris, K.P.; McShane, P.; Stickley, J.; Parslow, R.C. The relationship between blood lactate concentration, the Paediatric Index of Mortality 2 (PIM2) and mortality in paediatric intensive care. *Intensive Care Med.* 2012, 38, 2042–2046. [CrossRef]
- 143. Boigner, H.; Brannath, W.; Hermon, M.; Stoll, E.; Burda, G.; Trittenwein, G.; Golej, J. Predictors of mortality at initiation of peritoneal dialysis in children after cardiac surgery. *Ann. Thorac. Surg.* **2004**, *77*, 61–65. [CrossRef]
- Weber, R.W.; Stiasny, B.; Ruecker, B.; Fasnacht, M.; Cavigelli-Brunner, A.; Valsangiacomo Buechel, E.R. Prenatal Diagnosis of Single Ventricle Physiology Impacts on Cardiac Morbidity and Mortality. *Pediatr. Cardiol.* 2019, 40, 61–70. [CrossRef]
- 145. Amini, S.; Abbaspour, H.; Morovatdar, N.; Robabi, H.N.; Soltani, G.; Tashnizi, M.A. Risk factors and outcome of acute kidney injury after congenital heart surgery: A prospective observational study. *Indian J. Crit. Care Med.* **2017**, *21*, 847–851. [CrossRef]
- 146. Siddiqui, I.; Jafri, L.; Abbas, Q.; Raheem, A.; Haque, A.U. Relationship of serum procalcitonin, c-reactive protein, and lactic acid to organ failure and outcome in critically ill pediatric population. *Indian J. Crit. Care Med.* **2018**, 22, 91–95. [PubMed]
- 147. Nishibe, S.; Tsujita, M. The impact of intraoperative vasopressin infusion in complex neonatal cardiac surgery. *Interact. Cardiovasc. Thorac. Surg.* **2012**, *15*, 966–972. [CrossRef]
- Ressia, L.; Calevo, M.G.; Lerzo, F.; Carleo, A.M.; Petrucci, L.; Montobbio, G. Beneficial effect of fenoldopam mesylate in preventing peak blood lactate level during cardiopulmonary bypass for paediatric cardiac surgery. *Interact. Cardiovasc. Thorac. Surg.* 2014, 19, 178–182. [CrossRef]
- Garcia Guerra, G.; Joffe, A.R.; Senthilselvan, A.; Kutsogiannis, D.J.; Parshuram, C.S. Incidence of milrinone blood levels outside the therapeutic range and their relevance in children after cardiac surgery for congenital heart disease. *Intensive Care Med.* 2013, 39, 951–957. [CrossRef]
- Örmeci, T.; Alkan-Bozkaya, T.; Özyüksel, A.; Ersoy, C.; Ündar, A.; Akçevin, A.; Türkoğlu, H. Correlation between cerebral-renal near-infrared spectroscopy and ipsilateral renal perfusion parameters as clinical outcome predictors after open heart surgery in neonates and infants. *Artif. Organs* 2015, *39*, 53–58. [CrossRef]
- 151. Davidson, J.; Tong, S.; Hancock, H.; Hauck, A.; Da Cruz, E.; Kaufman, J. Prospective validation of the vasoactive-inotropic score and correlation to short-term outcomes in neonates and infants after cardiothoracic surgery. *Intensive Care Med.* **2012**, *38*, 1184–1190. [CrossRef] [PubMed]
- 152. Huang, S.C.; Wu, E.T.; Chen, Y.S.; Chang, C.I.; Chiu, S.; Chi, N.H.; Wu, M.H.; Wang, S.S.; Lin, F.Y.; Ko, W.J. Experience with extracorporeal life support in pediatric patients after cardiac surgery. *ASAIO J.* **2005**, *51*, 517–521. [CrossRef] [PubMed]
- 153. Kinoshita, M.; Hawkes, C.P.; Ryan, C.A.; Dempsey, E.M. Perfusion index in the very preterm infant. *Acta Paediatr.* 2013, 102, e398–e401. [CrossRef] [PubMed]

- Budniok, T.; ElSayed, Y.; Louis, D. Effect of Vasopressin on Systemic and Pulmonary Hemodynamics in Neonates. *Am. J. Perinatol.* 2020, *38*, 1330–1334. [CrossRef] [PubMed]
- 155. Sawada, M.; Ueda, K.; Matsuo, K.; Tokumasu, S.; Ogino, K.; Hayashi, T.; Saito, M.; Kubota, M.; Takahashi, A.; Watabe, S.; et al. Continuous renal replacement therapy in the NICU.; Ten years' experience in a singlecenter. *Pediatr. Nephrol.* **2015**, *30*, 2235.
- 156. Pugni, L.; Ronchi, A.; Bizzarri, B.; Consonni, D.; Pietrasanta, C.; Ghirardi, B.; Fumagalli, M.; Ghirardello, S.; Mosca, F. Exchange transfusion in the treatment of neonatal septic shock: A ten-year experience in a neonatal intensive care unit. *Int. J. Mol. Sci.* 2016, 17, 695. [CrossRef]
- 157. Algra, S.O.; Kornmann, V.N.N.; Van Der Tweel, I.; Schouten, A.N.J.; Jansen, N.J.G.; Haas, F. Increasing duration of circulatory arrest, but not antegrade cerebral perfusion, prolongs postoperative recovery after neonatal cardiac surgery. *J. Thorac. Cardiovasc. Surg.* **2012**, *143*, 375–382. [CrossRef]
- 158. Hoffman, T.M.; Wernovsky, G.; Atz, A.M.; Kulik, T.J.; Nelson, D.P.; Chang, A.C.; Bailey, J.M.; Akbary, A.; Kocsis, J.F.; Kaczmarek, R.; et al. Efficacy and safety of milrinone in preventing low cardiac output syndrome in infants and children after corrective surgery for congenital heart disease. *Circulation* 2003, 107, 996–1002. [CrossRef]
- 159. Talwar, S.; Bansal, A.; Sahu, M.K.; Singh, S.P.; Choudhary, S.K.; Airan, B. Vasoactive inotropic score and outcome assessment in cyanotic infants after cardiovascular surgery. *J. Card. Crit. Care* **2018**, *2*, 25–31. [CrossRef]
- 160. Bianchi, M.O.; Cheung, P.Y.; Phillipos, E.; Aranha-Netto, A.; Joynt, C. The effect of milrinone infusion on cerebral perfusion in neonates with congenital heart disease prior to cardiac surgery. *Arch. Dis. Child.* **2012**, *97*, A93–A94. [CrossRef]
- Soliman, R.M.; Mostafa, F.A.; Abdelmassih, A.; Sultan, E.; Mosallam, D. Patent ductus arteriosus in preterm infants; experience of a tertiary referral neonatal intensive care unit: Prevalence, complications, and management. *Egypt. Pediatr. Assoc. Gaz.* 2020, 68, 34. [CrossRef]
- 162. Rosenthal, J.; Ravi, P.; Eckersly, L.; Houshmandi, M.; Savard, W.; Hornberger, L. Impact of prenatal diagnosis of D transposition of the great arteries in the newborn who requires a balloon atrial septostomy. *Cardiol. Young* **2017**, *27*, S320–S321.
- 163. Ruth, V.J.; Raivio, K.O. Perinatal brain damage: Predictive value of metabolic acidosis and the Apgar score. *BMJ* **1988**, 297, 24–27. [CrossRef]
- 164. Dellenbach, P.; Haberey, P. Lactate as indicator for fetal and neonatal asphyxia. Lancet 1982, 1, 907. [CrossRef] [PubMed]
- 165. Trittenwein, G.; Pansi, H.; Graf, B.; Golej, J.; Burda, G.; Hermon, M.; Marx, M.; Wollenek, G.; Trittenwein, H.; Pollak, A. Proposed entry criteria for postoperative cardiac extracorporeal membrane oxygenation after pediatric open heart surgery. *Artif. Organs* 1999, 23, 1010–1014. [CrossRef]
- Luce, W.; Schwartz, R.; Beauseau, W.; Giannone, P.; Hashiguchi, B.; Cheatham, J.P.; Galantowicz, M.; Cua, C.L. Gastrointestinal morbidity for the hybrid approach to hypoplastic left heart syndrome. *Cardiol. Young* 2009, 19, 147.
- 167. Butts, R.J.; Scheurer, M.A.; Zyblewski, S.C.; Wahlquist, A.E.; Nietert, P.J.; Bradley, S.M.; Atz, A.M.; Graham, E.M. A composite outcome for neonatal cardiac surgery research. *J. Thorac. Cardiovasc. Surg.* **2014**, *147*, 428–433. [CrossRef]
- Cheifetz, I.M.; Kern, F.H.; Schulman, S.R.; Greeley, W.J.; Ungerleider, R.M.; Meliones, J.N. Serum lactates correlate with mortality after operations for complex congenital heart disease. *Ann. Thorac. Surg.* 1997, 64, 735–738. [CrossRef] [PubMed]
- 169. Oriot, D.; Nasimi, A.; Berthier, M.; Marlin, S.; Hubert, A.; Follet-Bouhamed, C. Lactate and anion gap in asphyxiated neonates. *Arch. Dis. Child. Fetal Neonat. Ed.* **1998**, *78*, F80. [CrossRef]
- 170. Ulate, K.P.; Yanay, O.; Jeffries, H.; Baden, H.; Di Gennaro, J.L.; Zimmerman, J. An Elevated Low Cardiac Output Syndrome Score Is Associated With Morbidity in Infants After Congenital Heart Surgery. *Pediatr. Crit. Care Med.* **2017**, *18*, 26–33. [CrossRef]
- 171. Janaillac, M.; Beausoleil, T.P.; Barrington, K.J.; Raboisson, M.-J.; Karam, O.; Dehaes, M.; Lapointe, A. Correlations between near-infrared spectroscopy, perfusion index, and cardiac outputs in extremely preterm infants in the first 72 h of life. *Eur. J. Pediatr.* **2018**, 177, 541–550. [CrossRef]
- 172. Cashen, K.; Costello, J.M.; Grimaldi, L.M.; Gowda, K.M.N.; Moser, E.A.S.; Piggott, K.D.; Wilhelm, M.; Mastropietro, C.W. Multicenter Validation of the Vasoactive-Ventilation-Renal Score as a Predictor of Prolonged Mechanical Ventilation After Neonatal Cardiac Surgery*. *Pediatr. Crit. Care Med.* 2018, 19, 1015–1023. [CrossRef]
- 173. Philpot, P.A.; Bhandari, V. Predicting the likelihood of bronchopulmonary dysplasia in premature neonates. *Expert Rev. Respir. Med.* **2019**, *13*, 871–884. [CrossRef]
- 174. Udine, M.; Borasino, S.; Alten, J.; Kirklin, J.; McNeal, S.; Xie, R.; Naftel, D.; Hock, K.; Dabal, R.; Cleveland, D. Early, mild fluid overload is associated with postoperative morbidity after neonatal cardiopulmonary bypass. *World J. Pediatr. Congenit. Heart Surg.* **2018**, *9*, NP24.
- Nasr, V.G.; Staffa, S.J.; Boyle, S.; Regan, W.; Brown, M.; Smith-Parrish, M.; Kaza, A.; DiNardo, J.A. Predictors of Increased Lactate in Neonatal Cardiac Surgery: The Impact of Cardiopulmonary Bypass. *J. Cardiothorac. Vasc. Anesth.* 2020, 35, 148–153. [CrossRef]
 Molteni, K.H. Blood lactate concentrations and neonatal sepsis. *J. Pediatr.* 1993, 123, 493–494. [CrossRef]
- 177. Lorenz, J.M.; Kleinman, L.I.; Markarian, K.; Oliver, M.; Fernandez, J. Serum anion gap in the differential diagnosis of metabolic acidosis in critically ill newborns. *J. Pediatr.* **1999**, *135*, 751–755. [CrossRef]
- 178. Fitzgerald, M.J.; Goto, M.; Myers, T.F.; Zeller, W.P. Early metabolic effects of sepsis in the preterm infant: Lactic acidosis and increased glucose requirement. *J. Pediatr.* **1992**, *121*, 951–955. [CrossRef] [PubMed]
- 179. Al Balushi, A.; Guilbault, M.-P.; Wintermark, P. Secondary Increase of Lactate Levels in Asphyxiated Newborns during Hypothermia Treatment: Reflect of Suboptimal Hemodynamics (A Case Series and Review of the Literature). AJP Rep. 2015, 6, e48–e58. [CrossRef] [PubMed]

- 180. Mastropietro, C.; Cashen, K.; Narayana, K.M.; Piggott, G.K.; Wilhelm, M.; Costello, J. Multicenter validation of the vasoactiveventilation-renal score for neonatal cardiac surgery. *Crit. Care Med.* **2016**, *44*, 108. [CrossRef]
- Qiu, L.S.; Liu, J.F.; Zhu, L.M.; Xu, Z.M. Evaluation on the early hemodynamic changes after cardiac surgery for congenital heart diseases in neonates. *Zhonghua Er Ke Za Zhi = Chin. J. Pediatr.* 2009, 47, 662–666.
- Baizat, M.; Zaharie, G.; Iancu, M.; Muresan, D.; Hăşmăşanu, M.; Procopciuc, L.M. Potential clinical predictors of suspected early and late onset sepsis (EOS and LOS) in preterm newborns: A single tertiary center retrospective study. *Clin. Lab.* 2019, 65, 1299–1308. [CrossRef]
- 183. König, K.; Drew, S.; Walsh, G.; Burke, E.; Barfield, C.; Watkins, A.; Collins, C. The relationship between B-type natriuretic peptide and echocardiographic and laboratory markers of circulatory status in preterm infants. *Monatsschr. Kinderheilkd.* **2011**, *159*, 98.
- Barberi, I.; Calabrò, M.P.; Cordaro, S.; Gitto, E.; Sottile, A.; Prudente, D.; Bertuccio, G.; Consolo, S. Myocardial ischaemia in neonates with perinatal asphyxia. Electrocardiographic, echocardiographic and enzymatic correlations. *Eur. J. Pediatr.* 1999, 158, 742–747. [CrossRef] [PubMed]
- Clark, D.A.; Munshi, U.K. Feeding associated neonatal necrotizing enterocolitis (Primary NEC) is an inflammatory bowel disease. *Pathophysiology* 2014, 21, 29–34. [CrossRef] [PubMed]
- Hannan, R.L.; Ybarra, M.A.; White, J.A.; Ojito, J.W.; Rossi, A.F.; Burke, R.P. Patterns of lactate values after congenital heart surgery and timing of cardiopulmonary support. *Ann. Thorac. Surg.* 2005, *80*, 1464–1468. [CrossRef]
- 187. Srinivasjois, R.; Nathan, E.; Doherty, D.; Patole, S. Prediction of progression of definite necrotising enterocolitis to need for surgery or death in preterm neonates. *J. Matern. Fetal Neonatal Med.* **2010**, *23*, 695–700. [CrossRef]
- Markkanen, H.K.; Pihkala, J.I.; Salminen, J.T.; Saarinen, M.M.; Hornberger, L.K.; Ojala, T.H. Prenatal diagnosis improves the postnatal cardiac function in a population-based cohort of infants with hypoplastic left heart syndrome. *J. Am. Soc. Echocardiogr.* 2013, 26, 1073–1079. [CrossRef]
- 189. Raghuraman, N.; Tuuli, M.G.; Macones, G.A.; Cahill, A.G.; Stout, M.J. Prediction of morbidity in SGA neonates: Are we using the right cord gas parameters to identify morbidity? *Am. J. Obs. Gynecol.* **2018**, *218*, S304. [CrossRef]
- 190. Waqar, T.; Haque, K.N. Umbilical cord blood gas and lactate levels as a marker of birth asphyxia in neonates with particular reference to resource limited countries. *Pak. Paediatr. J.* **2013**, *37*, 197–203.
- 191. Houshmandi, M.; Eckersley, L.; Savard, W.; Fruitman, D.; Mills, L.; Hornberger, L. Prenatal diagnosis improves the perioperative condition of neonates requiring surgical intervention for coarctation but is associated with longer preoperative stay. *Can. J. Cardiol.* **2017**, *33*, S40. [CrossRef]
- Aly, S.A.; Zurakowski, D.; Glass, P.; Skurow-Todd, K.; Jonas, R.A.; Donofrio, M.T. Cerebral tissue oxygenation index and lactate at 24 hours postoperative predict survival and neurodevelopmental outcome after neonatal cardiac surgery. *Congenit. Heart Dis.* 2017, 12, 188–195. [CrossRef]
- Polimenakos, A.C.; Rizzo, V.; El-Zein, C.F.; Ilbawi, M.N. Post-cardiotomy Rescue Extracorporeal Cardiopulmonary Resuscitation in Neonates with Single Ventricle After Intractable Cardiac Arrest: Attrition After Hospital Discharge and Predictors of Outcome. *Pediatr. Cardiol.* 2017, 38, 314–323. [CrossRef] [PubMed]
- 194. Gunn, J.K.; Beca, J.; Hunt, R.W.; Goldsworthy, M.; Brizard, C.P.; Finucane, K.; Donath, S.; Shekerdemian, L.S. Perioperative risk factors for impaired neurodevelopment after cardiac surgery in early infancy. *Arch. Dis. Child.* 2016, 101, 1010–1016. [CrossRef] [PubMed]
- 195. Neufeld, R.E.; Clark, B.G.; Robertson, C.M.; Moddemann, D.M.; Dinu, I.A.; Joffe, A.R.; Sauve, R.S.; Creighton, D.E.; Zwaigenbaum, L.; Ross, D.B.; et al. Five-year neurocognitive and health outcomes after the neonatal arterial switch operation. *J. Thorac. Cardiovasc. Surg.* 2008, 136, 1413–1421.e2. [CrossRef]
- 196. Khalid, O.M.; Harrison, T.M. Early Neurodevelopmental Outcomes in Children with Hypoplastic Left Heart Syndrome and Related Anomalies After Hybrid Procedure. *Pediatr. Cardiol.* **2019**, *40*, 1591–1598. [CrossRef]
- Freed, D.H.; Robertson, C.M.T.; Sauve, R.S.; Joffe, A.R.; Rebeyka, I.M.; Ross, D.B.; Dyck, J.D. Intermediate-term outcomes of the arterial switch operation for transposition of great arteries in neonates: Alive but well? *J. Thorac. Cardiovasc. Surg.* 2006, 132, 845–852.e2. [CrossRef] [PubMed]
- 198. Alton, G.Y.; Robertson, C.M.; Sauve, R.; Divekar, A.; Nettel-Aguirre, A.; Selzer, S.; Joffe, A.R.; Rebeyka, I.M.; Ross, D.B. Early childhood health, growth, and neurodevelopmental outcomes after complete repair of total anomalous pulmonary venous connection at 6 weeks or younger. *J. Thorac. Cardiovasc. Surg.* 2007, 133, 905–911. [CrossRef]
- Photiadis, J.; Sinzobahamvya, N.; Fink, C.; Schneider, M.; Schindler, E.; Brecher, A.M.; Urban, A.E.; Asfour, B. Optimal pulmonary to systemic blood flow ratio for best hemodynamic status and outcome early after Norwood operation. *Eur. J. Cardiothorac. Surg.* 2006, 29, 551–556. [CrossRef]
- El-Abd Ahmed, A.; Hassan, M.H.; Abo-Halawa, N.; Abdel-Razik, G.M.; Moubarak, F.A.; Sakhr, H.M. Lactate and intestinal fatty acid binding protein as essential biomarkers in neonates with necrotizing enterocolitis: Ultrasonographic and surgical considerations. *Pediatr. Neonatol.* 2020, *61*, 481–489. [CrossRef]
- Kuraim, G.A.; Garros, D.; Ryerson, L.; Moradi, F.; Dinu, I.A.; Garcia Guerra, G.; Moddemann, D.; Bond, G.Y.; Robertson, C.M.T.; Joffe, A.R. Predictors and outcomes of early post-operative veno-arterial extracorporeal membrane oxygenation following infant cardiac surgery. *J. Intensive Care* 2018, *6*, 1–12. [CrossRef]
- 202. Junior, L.K.O.; Carmona, F.; Aragon, D.C.; Gonçalves-Ferri, W.A. Evaluation of urine output, lactate levels and lactate clearance in the transitional period in very low birth weight preterm infants. *Eur. J. Pediatr.* **2021**, *180*, 91–97. [CrossRef]

- 203. Ricci, M.F.; Andersen, J.C.; Joffe, A.R.; Watt, M.J.; Moez, E.K.; Dinu, I.A.; Guerra, G.G.; Ross, D.B.; Rebeyka, I.M.; Robertson, C.M.T. Chronic Neuromotor Disability After Complex Cardiac Surgery in Early Life. *Pediatrics* 2015, 136, e922–e933. [CrossRef] [PubMed]
- 204. Simović, A.M.; Košutić, J.L.; Prijić, S.M.; Knežević, J.B.; Vujić, A.J.; Stojanović, N.D. The role of biochemical markers as early indicators of cardiac damage and prognostic parameters of perinatal asphyxia. *Vojnosanit. Pregl.* 2014, 71, 149–155. [CrossRef] [PubMed]

Disclaimer/Publisher's Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.